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Natural products are a rich source of diverse chemical compounds, many with 
pharmaceutical potential. Structural and biochemical investigations into the 
initiation steps of three natural product biosynthetic pathways were conducted. 
These findings contribute to the adaptation of natural products for industrial 
applications or for improved pharmaceutical properties as well as the discovery 
of novel enzymatic chemistry.  
 
The olefin synthase from the marine cyanobacterium Synechococcus sp. 
PCC7002 converts stearic acid to 1-nonadecene, a terminal olefin. Biologically 
generated length-controlled olefins have potential applications as lubricants, 
surfactants, chemical feedstocks, and biofuels. The fatty acid-ACP ligase (FAAL) 
domain of olefin synthase selects stearic acid for conversion to 1-nonadecene, 
dictating the length of olefin produced. Crystal structures of the SynFAAL guided 
the creation of a number of variants that led to the discovery of an electrostatic 
fatty acid selection mechanism and a better understanding of the basis of fatty 
acid length selectivity.  
 
The cahuitamycin pathway of Streptomyces gandocaensis natively produces 
three cahuitamycin variants, which are all potent inhibitors of Acinetobacter 
baumannii biofilm formation. Variation originates in the starter unit selected by 
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aryl-AMP ligase CahJ. Crystal structures of several CahJ-substrate complexes 
provided a structure-based explanation of substrate selectivity in the creation of 
natural cahuitamycins. Together with a comprehensive set of substrate selectivity 
data, the structure provides a roadmap for the creation of novel cahuitamycin 
congeners for future investigation as biofilm inhibitors.  
 
Apratoxin A from the marine cyanobacterium Moorea bouillonii contains a rare t-
butyl group. The steps for t-butyl biosynthesis likely involve novel enzymatic 
reactions by domains within AprA, the first protein of the biosynthetic pathway. A 
di-domain of AprA containing a type I S-adenosylmethionine dependent 
methyltransferase (MT) domain was shown to possess both acyltransfer and 
methylation activity. The crystal structure of the di-domain indicated that the MT 
domain performs both reactions and that the other domain is vestigial. 
 
The initiation steps are an important source of chemical diversity in natural 
product biosynthesis. Understanding the mechanisms of substrate recognition 
used by initiation enzymes could allow for the rational redesign of substrate 








1.1  Introduction 
Small-molecule natural products are complex biomolecules of stunning chemical 
and biological diversity. Bacteria and fungi are rich sources of these secondary 
metabolites, which are presumed to confer a competitive advantage to the 
producing organism within its environmental niche. Natural products represent an 
important source of pharmaceuticals due to their inherent bioactivity (1). 
Examples include cahuitamycin A, 1-nonadecene, and apratoxin A (Figure 1.1). 
Understanding the biosynthesis of natural products has multiple levels of impact 
ranging from basic scientific research on novel biochemical reactions to the 
tailoring of biosynthetic pathways to produce compounds with improved 
pharmaceutical or synthetic characteristics. 
 
Given the diversity of natural products, it is not surprising that nature employs 
many different biosynthetic schemes in their creation. This thesis focuses on two 
types of biosynthetic schemes: modular polyketide synthases (PKS) and 
nonribosomal peptide synthetases (NRPS). Modular biosynthetic pathways are 
distinguished by their use of modular groups of domains to catalyze each step of 
the extension and processing of a natural product intermediate. Multiple modules 
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are used in series to synthesize the final compound. This leads to a one-enzyme, 
one-reaction paradigm, which links every enzyme of the biosynthetic pathway to 
a specific functional group in the completed natural product. This thesis concerns 
the pathways illustrated in Figures 1.2-1.4. 
 
Figure 1.1  The natural product subjects of this thesis.  
 
A) The NRPS-produced cahuitamucyin A (2) has been shown to inhibit 
Acinetobacter baumanii biofilm formation. B) The PKS-produced long-chain olefin 
1-nonadecene (3) has potential industrial and biofuel applications. C) The hybrid 
PKS/NRPS-produced apratoxin A (4) has been shown to bind Sec61 causing cell 
death (5). 
 
Modular PKS and NRPS pathways use carrier proteins to covalently tether 
intermediates through a thioester linkage between a carboxylate of the 
intermediate and the thiol of a phosphopantetheine (Ppant) prosthetic group on 
the carrier protein. The acyl carrier protein (ACP) for PKS modules and the 
peptidyl carrier protein (PCP) for NRPS modules are related to each other and to 
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the ACP of fatty acid biosynthesis. The carrier protein shuttles intermediates 
between enzyme active sites and ensures that the intermediates are not lost from 
the biosynthetic machinery. Carrier protein delivery is well illustrated by the 
movements of the ACP in the cryo-EM structures of PikAIII (6,7). 
 
Polyketide synthase modules are functionally and evolutionarily related to type I 
metazoan fatty acid synthases (FAS) (8). A PKS module typically consists of 
between three and six domains, minimally an ACP domain, a ketosynthase (KS) 
domain, and an acyltransferase (AT) domain. Collectively, these domains extend 
the polyketide intermediate. In an important source of polyketide diversity, the AT 
domain selects an acyl-CoA extender unit and transfers the acyl group to the 
ACP (9). Most commonly, the AT selects malonyl-CoA or methylmalonyl-CoA; 
however, approximately a dozen acyl-CoA substrates are known (10). The ACP 
then shuttles the acyl group to the KS domain, where the upstream ACP has 
transferred its intermediate to a catalytic cysteine thiol.  The KS catalyzes the 
decarboxylative Claisen condensation of the upstream intermediate with the acyl-
ACP, thereby extending the intermediate polyketide chain by two carbon atoms. 
Additional diversity comes from the activities of up to three additional domains, 
ketoreductase (KR), dehydratase (DH) and enoylreductase (ER), which tailor the 
intermediate by reductive chemistry at the -carbonyl created in the extension 
reaction. Modular PKS pathways are reviewed in more detail by Hill and 
Staunton (11) and Smith, Skiniotis and Sherman (12). 
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Figure 1.2  The apraxotin A biosynthetic pathway (4).  
 
The domains and products of the pathway modules are color-coded: loading in 
purple, PKS extensions in orange, grey, pink, and red, β-branching in blue, 
NRPS extension in green, and offloading in cyan. 
 
The minimal NPRS module consists of an adenylation (A) domain, a 
condensation (C) domain, and a PCP domain. The A domain selects an amino 
acid, or related analogue, activates its carboxylate by adenylation from ATP, and 
transfers the amino acid to the PCP (10,13). The PCP then transports the 
selected amino acid to the C domain, which catalyzes the formation of a peptide 
bond between the peptide intermediate from the upstream PCP and the selected 
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amino acid. Some NRPS modules have C domains that also catalyze a 
cyclization reaction to form a thiazoline or oxazoline ring, and some modules also 
have tailoring enzymes such as N-methytransferase (NMT) domains, which 
methylate the backbone amide. The overall chemistry of NRPS pathways was 
reviewed in detail by Walsh (14). In addition to purely PKS or NRPS pathways, 
hybrid PKS/NRPS pathways are common. This is possible because of the 
common thioester tethering of intermediates by carrier proteins. The apratoxin 
biosynthetic pathway is an excellent example of a hybrid pathway with 
interspersed NRPS and PKS modules (Figure 1.2) (4). The extensions and 
modifications described above constitute only the middle portion of PKS or NRPS 
pathways, which must also initiate biosynthesis and offload the final products. 
Product release is commonly achieved with thioesterase domains that can 
catalyze either thioester hydrolysis to a linear product or intramolecular 
cyclization to a macrolactone or cyclic peptide.  
 
The topic of this thesis is the initiation step, among the most chemically diverse 
portions of modular natural product biosynthetic pathways. In many cases, the 
extension module machinery (e.g. NRPS A domains and PKS AT domains) is 
repurposed for the task of pathway initiation. However, the enzymes and 
mechanisms employed in loading an initial building block onto a carrier protein 
domain, reviewed from a chemical perspective by Moore and Hertweck (15), can 
be quite varied. Two broad categories of enzymes, the adenylate-forming 
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enzymes and the acyltransferases, are employed for pathway initiation (Figure 
1.5).  
 
1.2  Pathway Initiation by Adenylate-Forming Enzymes 
Adenylate-forming enzymes (AFE) constitute a large superfamily grouped by 
common chemistry (16). AFE family members activate a substrate carboxylate 
with ATP to form a 5'-adenylate intermediate that releases pyrophosphate. The 
activated intermediate is then transferred to a nucleophilic substrate, releasing 
AMP. For biosynthetic initiation, the nucleophile is the Ppant thiol of a carrier 
protein. The AFE superfamily includes a wide variety of enzymes including firefly 
luciferase, fatty acid CoA ligases (FACL), NRPS A domains, and aminoacyl-
tRNA synthetases. Two subclasses of AFE, NRPS A domains and fatty acid ACP 
ligases (FAAL), are used for natural product biosynthetic initiation. 
 
1.3  Initiation by NRPS A Domains 
The most straightforward AFE-based loading module consists of an NRPS A and 
a PCP. These loading modules function identically to their counterparts in 
extending modules. However, as the substrate selected by the loading A domain 
does not undergo a condensation reaction with an upstream peptide 
intermediate, an amino group is optional (Figure 1.5A). This allows for greater 
diversity in the starter unit selected by A domains, in principal limited only by the 
requirement for a carboxylate group that can be activated with ATP (10,17). 
Examples of non-amino acid starter units can be found in the cahuitamycin (2), 
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bacillaene (18), and rapamycin (19) pathways. These three pathways also 
demonstrate that initiation modules containing NRPS A domains are present at 
the beginning of NRPS, PKS and hybrid PKS/NRPS pathways.  
Figure 1.3  The cahuitamycins A-C biosynthetic pathway (2).  
 
The domains are color-coded: PCP (T) domains in tan, cyclization (Cy) domain in 
pink, adenylation (A) domains in green, condensation (C) domains in brown, and 
epimerization (E) in orange. Figure courtesy of Ashootosh Tripathi. 
 
1.3.1 Initiation of the cahuitamycin pathway 
The cahuitamycins are potent inhibitors of Acinetobacter baumanii biofilm 
formation, a common nosocomial pathogen (2). The cahuitamycins are produced 
by a bifurcated biosynthetic pathway that has flexibility in the starter unit used to 
initiate biosynthesis. The starter unit significantly affects biofilm inhibition activity 
and is selected by a stand-alone NRPS A domain, CahJ (Figure 1.3). CahJ 
natively selects either salicylic acid or 6-methylsalicylic acid leading to the 
production of cahuitamycin A-B or cahuitamycin C, respectively. CahJ also 
shows rare promiscuity by acting on the non-native substrate 5-methylsalicylic 
acid (5MSA) leading to the production of a new cahuitamycin analog (2). 
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Reinforcing the importance of the starter unit, the 5MSA-derived cahuitamycin 
analog has approximately twofold greater biofilm inhibition activity compared to 
the most active natural variant.  
 
1.4  Initiation by FAAL Domains 
Despite their similar function, it is clear by sequence identity that FAAL domains 
are derived from primary metabolism fatty acid-CoA ligases (FACL) and not 
NRPS A domains (20,21). FACL and FAAL enzymes both activate fatty acids 
with ATP to form fatty acyl adenlyates. FACL enzymes transfer the activated fatty 
acid to CoA while FAAL enzymes transfer the fatty acid to a partner ACP (Figure 
1.5B). A poorly conserved insert region that prevents FAAL enzymes from 
interacting with CoA distinguishes FAALs from FACLs (21-23). A number of 
FAAL enzymes have been identified at the beginning of natural product pathways 
including the columbamide PKS pathway (24), the jamaicamide hybrid 
PKS/NRPS pathway (25), and pyoverdine NRPS pathway (26). The range of 
fatty acid lengths in these natural product pathways is hexanoic acid (C6) to 
stearic acid (C18). FAALs are also employed in the biosynthesis of extremely 
long-chain fatty acids in Mycobacterium tuberculosis (27,28). 
 
1.4.1 Pathway initiation of the Synechococcus sp. PCC7002 olefin synthase 
Olefin synthases are small, polyketide-based biosynthetic pathways that convert 
fatty acids to olefins (29,30). Olefins have potential applications as biofuels, 
surfactants, lubricants, and chemical feedstocks (31). Olefin production is 
9  
initiated by an FAAL enzyme that selects the fatty acid that will be converted to 
an olefin. The fatty acid then undergoes a canonical PKS extension and 
ketoreduction. The extended fatty acid is then offloaded by a sulfotransferase 
and thioesterase domain pair, which generates a terminal olefin that is one 
carbon atom shorter than the extended fatty acyl group (32-34). In the case of 
the Synechococcus sp. PCC 7002 olefin synthase, stearic acid (octadecanoic 
acid) is converted to 1-nonadecene (Figure 1.4) (3,30). All identified olefin 
synthases produce long-chain olefins (29) that are too long for current industrial 
applications (31). An understanding of the FAAL domain's fatty acid selection 
mechanism is required to engineer olefins of more useful chain length.  
Figure 1.4  The olefin synthase pathway from Synechococcus sp. PCC7002 (3). 
 
The domains and products of the pathway modules are color-coded: loading in 
blue, PKS extension in red, and offloading in green. 
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1.5  Pathway Initiation by Acyltransferase Enzymes 
Natural product acyltransferase enzymes transfer an acyl group from a specific 
acyl-CoA to an ACP Ppant thiol. The majority of pathways that use an acyl-
transfer initiation strategy employ a standard PKS AT domain; however, some 
pathways use a GCN5-related N-acetyltransferase (GNAT)-related domain (35). 
The transfer of an acyl group from a CoA thioester to a Ppant thiol is isoenergetic 
(36) and should require only proper active site geometry, i.e. no catalytic 
residues are required. Thus it is possible that other, as-yet-unidentified classes of 
enzymes may catalyze acyltransfer reactions. 
 
1.6  Initiation by PKS AT Domains 
Considered the canonical form of PKS initiation, loading modules containing AT 
domains function similarly to their counterparts in extension modules and consist 
of an AT domain and an ACP (37). Loading module ATs act identically to other 
AT domains by selecting the proper acyl-CoA and transferring the acyl group to 
the ACP, via an acyl-enzyme intermediate at a catalytic Ser. The majority of 
pathways are initiated with either acetyl- or propionyl-ACP, which can be 
generated by direct transfer from acetyl- or propionyl-CoA or by the 
decarboxylation of malonyl- or methylmalonyl-ACP through the action of an 
additional decarboxylating KS enzyme (Figure 1.5C) (38,39). Although most 
pathways are initiated with acetyl- or propionyl-ACP, pathways utilizing isobutryl-
CoA (40), benzoyl-CoA (41), and 2-methylbutryl-CoA (42) as a starter unit are 
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common. As a more extreme example, the borrelidin pathway initiates with 
cyclopentanedicarboxylate (43), a significant departure from the common acetyl 
and propionyl starter units and an example of the remarkable adaptability of AT 
domains.  
Figure 1.5  The four major routes to initiation of natural product biosynthesis.  
 
A) Initiation by NRPS A domains utilizes ATP to activate amino acids or related 
molecules, and load them onto PCP domains. For amino acids, R1 is NH3 and R2 
is an amino acid side chain. For non-amino acids molecules, R1 and R2 can be 
any moiety. B) FAAL domains initiate biosynthesis similarly to A domains but 
utilize fatty acids as substrates instead of amino acids. R3 is (CH2)nCH3 were n is 
typically between 4 and 16. C) PKS AT domains initiate biosynthesis by 
transferring acyl groups from CoA to an ACP domain. D) GNAT-based loading 
modules decarboxylate malonyl-CoA to acetyl-CoA and then transfer the acetyl 
group to an ACP domain. 
 
1.7  Initiation by GNAT-like Domains 
First discovered in a natural product pathway in the pederin biosynthetic pathway 
(44) and first characterized in the curacin biosynthetic pathway (35), initiation by 
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GNAT domains has been identified in at least twelve pathways. As a superfamily, 
GNAT domains catalyze the transfer of acyl groups from acyl-CoA to a diverse 
group of substrates and are found across all domains of life (45). The family was 
first defined by the yeast general control non-repressible 5 (GCN5)-related 
histone N-acetyltransferase (46). In the context of natural product pathways, 
GNAT enzymes act similarly to AT domains to transfer of an acyl group from CoA 
to an ACP, but without use of an acyl-enzyme intermediate (Figure 1.5D). 
Investigations of the curacin loading module (CurA) GNAT demonstrated that the 
enzyme utilizes malonyl-CoA as a substrate, which it decarboxylates prior to acyl 
transfer (35). Examples of loading modules containing GNAT domains are know 
from gene cluster assignments across diverse organisms such as sponge 
symbionts (44,47,48), myxobacteria (49), and cyanobacteria (4,50,51); however, 
only the CurA GNAT has been characterized biochemically or structurally. A 
subset of GNAT-based loading modules also contain putative methyltransferase 
(MT) domains, which are proposed to methylate the acetyl-ACP generated by the 
GNAT domain (49,50). 
 
1.7.1 Initiation of the apratoxin pathway 
Apratoxin A has been shown to bind to the translocation protein Sec61, inhibiting 
cotranslational translocation and causing cell death (5,52,53). The loading 
module of the apratoxin pathway (AprA) contains two putative MT domains, a 
feature that has not yet been observed elsewhere (Figure 1.1) (4). Additionally, 
the AprA GNAT domain aligns poorly with the other loading module GNATs and 
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appears to lack the amino acids responsible for the decarboxylation activity of the 
CurA GNAT. Together this may indicate that AprA utilizes a unique mechanism 
of biosynthetic initiation despite the presence of a GNAT domain. The product of 
the AprA loading module is a t-butyl containing pivalyl-ACP, both of which are 
rarely seen in natural product pathways. The putative MT domains are proposed 
to create the pivalyl-ACP by performing three SAM-dependent methylations on 
the GNAT generated acetyl-ACP.  
 
1.8  Thesis Overview 
The studies described in the following chapters seek to broaden our 
understanding of the initiation steps of natural product biosynthesis though 
structural and biochemical investigations into three biosynthetic pathways: the 
olefin synthase of the marine cyanobacterium Synechococcus sp. PCC 7002, the 
cahuitamycin pathway of Streptomyces gandocaensis, and the apratoxin 
pathway of the marine cyanobacterium Moorea bouillonii. For the 
Synechococcus sp. PCC 7002 olefin synthase, crystal structures of the FAAL 
domain guided the creation of a number of variants that led to the 
characterization of an electrostatic fatty acid selection mechanism and a better 
understanding of fatty acid length selectivity. For the cahuitamycin pathway, 
crystal structures of several CahJ-substrate complexes provided a structure-
based explanation of substrate utilization probed with a large, chemically diverse 
set of substrates. Lastly, for the apratoxin pathway structural and biochemical 
data is presented showing that the loading module GNAT is significantly different 
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from the GNAT of the curacin pathway in both structure and function. 
Additionally, structural data are presented showing that the second MT domain is 




An Electrostatic Fatty Acid Selection Mechanism by the Olefin Synthase 
FAAL domain from Synechococcus sp. PCC7002 
 
2.1  Notes 
This chapter is being prepared for publication in a manuscript titled " An 
Electrostatic Fatty Acid Selection Mechanism by the Olefin Synthase FAAL 
domain from Synechococcus sp. PCC 7002" with the authors: Sikkema AP, 
Sturgis R, Gerwick WH, Sherman DH, Smith, JL. 
 
Author Contributions: 
A.P.S. and J.L.S. designed experiments. A.P.S and R.S performed experiments. 
A.P.S. wrote the manuscript. A.P.S. and J.L.S. edited the manuscript. 
 
2.2  Abstract 
Long and medium chain α-olefins have applications as lubricants, surfactants, 
chemical feedstocks, and biofuels. The marine cyanobacterium Synechococcus 
sp. PCC 7002 contains an olefin synthase that converts stearic acid to 1-
nonadecene. Stearic acid is selected and activated by the fatty acid-ACP ligase 
(FAAL) domain at the N-terminus of the olefin synthase prior to canonical 
reactions of polyketide synthase (PKS) extension and -ketoreduction. The 
extended fatty acid is then sulfonated at the -hydroxy position and offloaded via 
concerted desulfation and decarboxylation to generate an α-olefin product that is 
one carbon longer than the fatty acid substrate. The length of the selected fatty 
acid selected by the FAAL domain dictates the length of the final α-olefin. 
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Understanding the FAAL mechanism of fatty acid chain length selection would 
enable the engineering of olefin synthases to produce specific α-olefins. Here 
crystal structures of SynFAAL in complex with AMP and acyl adenylates is 
report. The structures guided the creation of a number of SynFAAL variants that 
led to the characterization of a mechanism for chain-length selectivity of fatty acid 
substrates which is supported with biochemical data.  
 
2.3  Introduction 
Microbial production of hydrocarbons has drawn increasing interest as a potential 
alternative to petroleum-based fuels and chemicals (31,55,56). Cyanobacteria 
have two major pathways for the conversion of fatty acids to hydrocarbons (29). 
The majority of cyanobacteria contain a “FAAR/ADO” system, which converts 
fatty acids to alkanes via the dual action of a fatty acyl acyl-carrier-protein (ACP) 
reductase (FAAR) and an aldehyde deformylating oxygenase (ADO). 
Alternatively, some cyanobacteria contain olefin synthases, small biosynthetic 
pathway composed of one or two polypetides that convert fatty acids to α-olefins. 
Although α-olefins have applications as energy sources, they have potentially 
higher value as lubricants, surfactants and chemical feedstocks (31).  
 
17  
Olefin synthases consist of six enzymatic domains: fatty acid ACP ligase (FAAL), 
ketosynthase (KS), acyltransferase (AT), ketoreductase (KR), sulfotransferase 
(ST), and thioesterase (TE), and two ACP domains (ACP1 and ACP2) (Figure 
2.1A). The FAAL initiates biosynthesis by selecting a fatty acid, activating it by 
adenylation from ATP, and transferring it to the phosphopantetheine cofactor of 
ACP1 (Figure 2.1B). The fatty acyl chain then undergoes canonical reactions of 
 
Figure 2.1  Olefin biosynthesis and FAAL activity.  
 
A) The olefin synthase pathway from Synechococcus sp. PCC 7002. B) The 
two-step FAAL reaction; 5'-adenylation and acyl transfer to ACP. 
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polyketide synthase (PKS) extension and -ketoreduction, catalyzed by the AT, 
KS and KR (12). The two-carbon extension reaction transfers the fatty acyl chain 
to ACP2. -olefin production is completed by the unusual ST and TE offloading 
reactions in which -hydroxyacyl-ACP sulfonation is followed by chain release via 
concerted desulfation and decarboxylation to generate an -olefin product that is 
one carbon longer than the fatty acid substrate (32-34). 
 
The Synechococcus sp. PCC 7002 olefin synthase has been characterized in 
vivo to produce 1-nonadecene. However, feeding odd-number chain-length fatty 
acids to Synechococcus sp. PCC 7002 resulted in even-number chain-length 
olefins, for example feeding heptadecanoic acid resulted in 1-octadecene (3). In 
vivo, olefin production is required for survival at lowered growth temperatures, 
indicating a biological function in the regulation of membrane fluidity (30). The 
chain length of α-olefins affects important chemical and physical properties such 
as energy density and melting temperature, which are critical to their use as 
biofuels and in industrial applications (31). Thus, the ability to control olefin chain 
length though protein engineering could be a major advantage of producing 
olefins in bacterial systems. In order to achieve such control the mechanism of 
FAAL selectivity of fatty acid chain-length must be understood. 
 
FAALs are members of the adenylate-forming enzyme superfamily, which 
includes nonribosomal peptide synthetase (NRPS) adenylation domains, fatty 
acid-CoA ligases (FACLs), and firefly luciferase (16). The FAALs are 
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distinguished from FACLs by an ~20-amino acid insertion, which is proposed to 
prevent formation of a CoA binding pocket in the N-terminal domain where it is 
located. Removal of the insertion restores the ability of an FAALs to transfer fatty 
acids to CoA (21,22).  
 
FAALs are found in number of biological contexts. Those most closely related to 
the olefin synthase FAALs are within the biosynthetic pathways of natural 
products, including jamaicamide (25), hectochlorin (57), and columbamide (24). 
The  natural-product FAALs act on shorter fatty acids than olefin synthase FAALs 
(hexanoic acid for jamaicamide and hectochlorin and dodecanoic acid for 
columbamide), indicating a variable selectivity in the substrate chain-length. 
JamA, the FAAL from the jamaicamide pathway, can act on fatty acids between 5 
and 7 carbons long in a variety of saturation states (58,59). Mycobacterium 
tuberculosis also contains a number of FAALs (27) such as those linked to the 
production of the mycolic acids (23). Crystal structures have been reported for M. 
tuberculosis FadD32 FAAL, a potential drug target (60) and for a few putative 
FAALs of unknown function from E. coli and L. pneumophila (20). 
 
To improve our understanding of the substrate selectivity of FAALs, we examined 
the Synechococcus sp. PCC 7002 olefin synthase FAAL domain (SynFAAL). 
Here we report the crystal structure of SynFAAL in complex with AMP and acyl 
adenylates together with biochemical data on the chain-length selectivity for acyl-
ACP1 (SynACP1) substrates. We also demonstrate that the chain-length 
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selectivity can be manipulated by mutagenesis of the FAAL fatty acid binding 
tunnel.  
 
2.4  Results 
2.4.1 Biochemical Characterization of SynFAAL 
The fatty acid ACP ligase activity of SynFAAL was assayed by HPLC revealing a 
robust conversion of holo-ACP to stearoyl-ACP (Figure 2.2A). Next, we 
evaluated SynFAAL selectivity for fatty acid chain length via a high-throughput 
malachite green colorimetric assay (61). In this coupled assay, the 
pyrophosphate produced by the fatty acid adenylation step is converted by 
inorganic pyrophosphatase to orthophosphate (Pi), which is detected with 
malachite green. We tested SynFAAL with a panel of fatty acids from four to 
twenty carbons in length. Surprisingly, SynFAAL had a bimodal substrate length 
profile. Holo-ACP1 was acylated with the natural substrate, stearic acid 
(octadecanoic acid - C18) at an apparent rate of 0.23 ± 0.03 μM/min-1 whereas 
palmitoylation (hexadecanoic acid - C16) was threefold slower (0.085 ± 0.009 
μM/min-1). In contrast, acylation with tetradecanoic (C14), dodecanoic (C12), and 
decanoic (C10) acids was up to twofold faster than from the native substrate 
(0.32 ± 0.04 μM/min-1, 0.49 ± 0.06 μM/min-1, 0.53 ± 0.04 μM/min-1, respectively), 
and acylation with substrates shorter than C10 or longer than C18 was 3-6 times 
slower than the C18 natural substrate (Figure 2.2B). It is likely that SynFAAL 
distinguishes stearic acid (C18) from palmitic acid (C16) but not from C10 - C14 
fatty acids, which are expected to have very low concentrations in vivo.  Hence 
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we conclude that the greater activity observed with C10 - C14 substrates reflects 
a lack of selectivity against them. 
 
2.4.2 Overall Structure of SynFAAL 
To aid our understanding of substrate selectivity, we determined the crystal 
structure of SynFAAL at 2.0Å. Screening yielded SynFAAL crystals in the 
presence of ATP (Table 2.1). The crystals grew, with poor reproducibility, as 
clusters of plates that required raster scanning with a 10-m diameter X-ray 
beam to identify sites where the beam intercepted a single crystal. Size exclusion 
chromatography indicated that SynFAAL is a monomer in solution, and crystals 
have two monomers in the asymmetric unit. Both monomers are in the same 
 
Figure 2.2  SynFAAL fatty acids ligase activity with ACP.  
 
A) HPLC elution of SynACP1 species in a reaction mix with SynFAAL, stearic 
acid and ATP (red trace) compared to a negative control without SynFAAL 
(blue trace). Samples were incubated overnight at 20°C. Some apo-ACP1 
contaminates both samples as the ACP1 was incompletely loaded with the 
phosphopantetheine cofactor. The identity of stearoyl-ACP1 at 17.9 min was 
confirmed by mass spec analysis. B) Activity of SynFAAL on a panel of even-
number fatty acids of chain length between 4 (C4) and 20 (C20) carbons 
measured by a malachite-green-based pyrophosphate detection assay. 
Negative controls include NFC: no fatty acid, NEC: no enzyme, NAC: no ACP. 
Error bars indicate one standard deviation of 3 replicates in triplicate. 
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conformation. SynFAAL has a similar structure to other members of the FAAL 
subfamily of adenylate-forming enzymes (20,23,62), consisting of an N-terminal 
domain (amino acids 2-449) and a smaller C-terminal domain (450-570). The 
closest homologue of known structure is the L. pneumophila fatty acyl-adenylate 
ligase (20) (43% identity, RMSD 0.88Å, PDB code: 3LNV), which was used to 
solve the structure of SynFAAL by molecular replacement. The fatty acid binding 
pocket is contained within the N-terminal domain and the ATP binding pocket is 
formed at the interface of the two domains (Figure 2.3). Co-crystallization with 







Figure 2.3  Structure of SynFAAL at 2.0Å.  
 
AMP and PPi bind between the N-terminal domain (green) and the C-terminal 
domain (blue). Ligands are shown as ball-and-stick in atomic coloring 






Table 2.1  X-ray Data Collection and Refinement Statistics 




Space group C2 C2 C2 
Cell dimensions a/b,c (Å) 201.3, 60.9, 95.9  199.1, 60.6, 95.1 201.2, 60.9, 95.8  
α,β,γ (°)  90, 101.2, 90  90, 101.1, 90 90, 101.1, 90  
X-ray source APS 23ID-D APS 23ID-D APS 23ID-B 
Wavelength (Å) 1.033 1.033 1.033 
dmin (Å) 1.99 (2.11-1.99)
1 2.13 (2.26-2.13) 2.25 (2.38-2.25) 
Rmerge 0.094 (0.647)  0.126 (0.753) 0.144 (0.663) 
Wilson B factor 34.2 34.4 36.8 
Avg I/σ(I) 8.96 (1.49) 8.20 (1.79) 6.58 (1.61) 
Completeness (%) 97.0 (86.9) 99.3 (97.1) 99.2 (97.4) 
Multiplicity 3.08 (2.63) 4.05 (3.94) 3.41 (3.45) 






CC1/2 0.995 (0.708) 0.992 (0.684) 0.990 (89.6) 
CC* 0.999 (0.911) 0.998 (0.901) 0.997 (0.972) 
Refinement    
Data range (Å) 29.82-1.99 50.50-2.13 29.4-2.25 
Reflections used in 
refinement 
75,765 62,444 54,183 
Rwork/Rfree 18.7/23.9 19.9/25.1 20.4/27.5 
Number of non-hydrogen 
atoms 




  protein 8,654 8,665 8,652 
  ligands 112 112 68 
  water 661 378 319 
Amino acid residues 1,134 1,136 1,135 
Deviation from ideality    
  bond lengths (Å) 0.009 0.010 0.009 
  bond angles (°) 1.05 1.14 1.23 
Average B-factor 36.1 36.8 42.5 
  macromolecules 35.6 36.8 42.5 
  ligands 40.6 39.1 47.7 
  solvent 41.0 36.6 39.7 
Ramachandran plot    
  favored (%) 98.0 96.5 96.6 
  allowed (%) 1.9 3.3 3.0 
  outliers (%) 0.1 0.2 0.4 
1Values in parentheses pertain to outermost shell of data. 
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A fatty acid binding pocket is apparent as a long, largely hydrophobic tunnel 
extending into the N-terminal domain. Sparse density in the tunnel may be a co-
purifying fatty acid at low occupancy or poorly localized waters. I attempted to 
crystallize a SynFAAL stearoyl adenylate complex, however the addition of fatty 
acid to the crystallization solutions prevented crystal growth and I was unable to 
soak fatty acids into previously grown crystals. 
 
2.4.3 Crystal Contact Engineering  
The challenge of producing single crystals of SynFAAL and a lack of success in 
crystallizing a complex with the stearoyl adenylate intermediate led me to 
investigate crystal lattice contacts that might be improved by mutagenesis. I 
identified an unfavorable contact between Arg336 side chains in two FAAL 
molecules at a crystallographic twofold axis (Figure 2.4). An alanine substitution 
at this position improved the reproducibility and speed of crystallization and 
increased the frequency of single crystal growth. SynFAAL/R336A had activity 
and substrate selectively almost identical to the wild type and was used for all 
subsequent crystal structures (Table 2.2).  
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Figure 2.4  Crystal Packing of SynFAAL.  
 
A) Packing of wild type SynFAAL in crystals of space group C2, viewed along 
the crystallographic b axis. The two independent SynFAAL molecules are 
rendered in orange and cyan. The poor lattice contact is indicated with a black 
line. The red box indicates the portion of the lattice shown in part C. B) The 
position of Arg336 in SynFAAL is more than 25 Å from the site of acyl transfer. 
Bound AMP and PPi are rendered in magenta ball-and-stick to show the 
location of the active site. R336 shown in orange ball-and-stick. C) Close up 
view of the weak contact around the crystallographic twofold axis with 
contacting amino acids shown in ball-and-stick. D) Electron density at the 
lattice contact (2Fo-Fc contoured at 1σ) with protein atoms shown in ball-and-
stick. In neighboring molecules, the Arg336 C atoms are only 6 Å apart and 
their side chains are poorly ordered beyond the C atom due to electrostatic 
repulsion. Substitution of Ala at position 336 resulted in more reproducible 
crystallization and higher quality crystals.  
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2.4.4 Fatty Acid Binding Tunnel of SynFAAL 
The improved crystallization behavior of SynFAAL/R336A allowed us to capture 
a stearoyl adenylate intermediate (Table 2.1, Figure 2.5). The C18 stearoyl chain 
binds in the long, hydrophobic binding tunnel as expected, and occupies the full 
length of the tunnel (Figure 2.5C and D). The tunnel lies between the curved -
sheet and two helices of the core domain. It is narrow for much of its length, but 
has a triangular bulge containing three ordered water molecules near the C-12 
position of the stearoyl chain (Figure 2.5C). Surprisingly, the fatty acid does not 
form a hydrogen bond with SynFAAL; the carbonyl oxygen of the thioester is 
pointed toward the adenine ring of AMP instead of the protein (Figure 2.5A). 
 
2.4.5 Electrostatic Lock for Fatty Acid Selection 
Although the fatty acid binding tunnel has a predominantly nonpolar surface 
(Figure 2.6A), it has a positive surface potential at the top and a negatively 
charged surface at the bottom (Figure 2.6B and C). As expected, the AMP and 
PPi sites are positively charged. Conversely, a strong negative patch near the 
bottom of the binding tunnel between the C15 and C17 positions is due to the 
Asp199 side chain (Figure 2.7A). I speculated that the negative charge at the 
C15-C17 position in the tunnel may be an “electrostatic lock” that effectively 
reduces selectivity for palmitic acid (C16). To explore this possibility, we 
characterized the activity of SynFAAL/D199L and SynFAAL/D199A with the 
panel of fatty acids (Figure 2.7B). Importantly, both nonpolar substitutions 
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resulted in an approximately two-fold increase in activity with palmitic acid (C-16) 
as well as slight increases with tetradecanoic acid (C-14) and stearic acid (C-18). 
Figure 2.5  Binding of fatty acyl chains in the SynFAAL substrate tunnel.  
 
Electron density for stearoyl adenylate in the substrate tunnel. Fo-Fc 
simulated-annealing omit density at 3σ (A) (green mesh) and 2σ (B) (yellow 
mesh). Atoms are shown in ball-and-stick with cyan C for the protein and 
magenta C for stearoyl adenylate. C) Length and shape of the substrate 
binding tunnel. The tunnel surface is rendered in gray, stearoyl adenylate in 
spheres and PPi in ball-and-stick. D) Position of stearoyl adenylate in the 
overall SynFAAL structure. SynFAAL is rendered as in Fig. 2 with ligands 
shown as in C.  
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Figure 2.6  Surface features of the SynFAAL substrate tunnel.  
 
A) Stearoyl adenylate (spheres) and surrounding amino acids (ball-and-stick 
with green C). B) and C) Electrostatic surface potential of the substrate binding 
tunnel, colored from electronegative to electropositive (red to blue, -10 to +10 
kT). The top of the tunnel is highly electropositive for nucleotide binding (B), 
whereas the middle is largely hydrophobic for fatty acid binding (C). The 
bottom of the tunnel is electronegative.  
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To further explore how the charge of the binding tunnel affects substrate 
selection we shortened the substrate tunnel by substituting Ile for Ala at position 
229 near the bottom of the tunnel. SynFAAL/A229I (Figure 2.6A) had an almost 
3-fold increase in activity with palmitic acid relative to the wild type while not 
significantly altering activity with other fatty acids (Figure 2.7C). Additionally, in 
the crystal structure of the SynFAAL/R336A/A229I complex with palmitoyl 
adenylate the bottom of the binding pocket expands slightly outward to 
accommodate the larger isoleucine which prevents the binding tunnel from 
decreasing significantly in size (Figure 2.7D). The isoleucine substitution 
increased the overall hydrophobicity of the bottom of the tunnel. The bound 
palmitoyl adenylate adopts a very similar conformation to stearoyl adenylate in 




Figure 2.7  Electrostatic lock for fatty acid selection.  
 
A) Electrostatic surface potential of the bottom of the substrate binding tunnel.  
Asp199 accounts for the negative surface potential in this region. The tunnel 
surface, bound stearoyl adenylate and Asp199 are rendered as in Fig. 6. B) 
and C) Activity of SynFAAL variants, D199L and D199A (B) and A229I (C) on a 
panel of fatty acids of chain length between 4 (C4) and 20 (C20) carbons. 
Negative controls are as in Fig. 2. Error bars indicate one standard deviation of 
at least two replicates in triplicate. D) Overlay of wild type SynFAAL stearoyl 
adenylate complex and the SynFAAL/R336A/A22I palmitoyl adenylate complex 
(RMSD 0.3 Å). WT is shown in cyan and A229I variant is shown in green with 
amino acids shown in ball-and-stick and protein surfaces as meshes. Stearoyl 
adenylate (magenta) and palmitoyl adenylate (yellow) shown in ball-and-stick. 
The protein surfaces show the shift of the bottom of the tunnel in the upward 
direction with A229I. 
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2.4.6 Fatty Acid Selectivity in the Binding Tunnel  
To probe SynFAAL chain-length selectivity, we made a number of substitutions 
to residues lining the fatty acid binding tunnel. These efforts were guided by a 
sequence alignment of cyanobacterial FAALs with known substrates of differing 
length: C6 (JamA and HctA), and C12 or longer (SynFAAL, MooreaFAAL and 
ColA) (Figure 2.8A). We identified three differentially conserved positions in the 
two groups: Phe197, Met215, and Gly219 (SynFAAL numbering) for the long-
substrate FAALs and Trp197, Tyr215 and Asp219 for the C6-selective FAALs 
(Figure 2.8B and C). We also identified one position, Gly205, that may 
discriminate between C18 (SynFAAL) and C16 (MooreaFAAL) (29) substrates 
and C12 (ColA FAAL) (24) substrates. Each of these positions in SynFAAL was 
mutagenized to its counterpart in the shorter-chain FAALs, along with a 
F197W/M215Y double substitution, and their activities with the panel of fatty 
acids were compared to the wild type. 
Figure 2.8  Amino acids affecting fatty acid selectivity.  
 
A) Sequence alignment of six cyanobacterial FAALs in the region that lines the 
substrate tunnel. Red stars indicate positions that are differentially conserved 
among sequences of FAALs with natural substrates longer than six carbons 
(above the horizontal line), and those that act on hexanoic acid (below the 
line). Residue 205 (blue star) appears to be a selectivity filter for substrate 
length in ColA (C12, Phe205) compared to SynFAAL and MooreaFAAL (C18, 
Gly205). B) and C) Positions of differentially conserved amino acids relative to 
the fatty acid binding tunnel. The tunnel surface is rendered as in Fig. 5, and 
highlighted amino acids and stearoyl adenylate as in Fig. 6. D) and E) Activity 
of SynFAAL variants, F197W and G219D (D) and M215Y (E) relative to the 
wild type on a panel of fatty acids with chain length between 4 (C4) and 20 
(C20) carbons. Negative controls are as in Fig. 2. Error bars indicate one 
standard deviation for at least 2  replicates in triplicate. Accession numbers for 
sequences: SynFAAL: CP000951.1, MooreaFAAL:  KF550302.1, ColA: 
KP715425.1, JamA: AY522504.1, HctA: AY974560.1. 
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Phe197 and Gly219 are located halfway along the binding tunnel near the 
stearoyl C12 position. Relative to the wild type, SynFAAL/F197W and 
SynFAAL/G219D had significantly decreased activity for nearly all substrates and 
no detectable activity with fatty acids longer than 12 carbons (Figure 2.8D). 
Despite the lower activity, SynFAAL/G219D had a strong preference for decanoic 
acid whereas SynFAAL/F197W had similar activity with octanoic and decanoic 
acids with levels approximately 50% that of SynFAAL with stearic acid. Met215 is 
located at a bend near the top of the substrate tunnel between the C3 and C7 
positions (Figure 2.8C). Surprisingly, given its location, the M215Y variant had 
little impact on activity with fatty acids shorter then palmitic acid (C16). However, 
activity with palmitic acid was increased relative to wild type, and activity with 
stearic acid was nearly abolished (Figure 2.8E). SynFAAL/G205F and the doubly 
substituted SynFAAL/F197W/M215Y had no detectable activity with any of the 
tested substrates (Table 2.2).  
 
2.5  Discussion 
Microbial production of α-olefins for biofuels and industrial applications 
(surfactants, lubricants, feedstocks) shows promise. For olefin synthases to be a 
suitable means of production, the length of the produced olefin must be 
controllable. Understanding the FAAL mechanism of fatty acid chain length 
selection would enable the engineering of olefin synthases to produce specific α-
olefins. Towards this end I determined AMP and acyl adenylates complex 
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structures of synFAAL by X-ray crystallography. I also performed biochemical 
assays investigating the chain-length selectivity for fatty acid substrates. 
SynFAAL represents the first FAAL domain from an olefin synthase to be purified 
and characterized and the first FAAL from cyanobacteria to be crystallized. The 
structures guided the creation of a number of SynFAAL variants that led to the 
characterization of an electrostatic fatty acid selection mechanism and an 
understanding of some aspects of the fatty acid length selectivity. 
 
Determining the structure of SynFAAL was challenging. An initial crystal 
condition was difficult to obtain and took significant optimization. After 
optimization crystals still had high mosaicity. Dealing with these issues required 
extensive screening of crystals and the use of small beam sizes combined with 
rastering to find areas of the crystals with suitable diffraction. During attempts to 
obtain a SynFAAL structure in complex with stearyl adenylate it was discovered 
that the addition of fatty acids negatively impacted crystal formation and 
diffraction quality crystals could not be obtained. Attempts to soak fatty acids into 
already formed crystal were unsuccessful as well. Therefore, crystal contact 
engineering was used to generate more robust crystals that could tolerate the 
addition of fatty acids in co-crystallization. The crystal contact containing Arg336 
was identified as the best target for engineering and replacement of the arginine 
with alanine resulted in larger and more robust crystals (Figure 2.4). Improved 
crystals were more tolerant of fatty acids and resulted in the strearyl adenylate 
structure.  
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The bimodal substrate utilization profile of SynFAAL is unprecedented among the 
studied FAAL enzymes (Figure 2.2B) (26,63). In previous cases the FAAL 
enzyme displayed high selectivity for one fatty acid chain-length with a rapid drop 
off in activity with changes in length. A clearer picture of the biological reason for 
the bimodal distribution can be gained by looking at the substrates available in 
vivo. Previous work has shown that Synechococcus sp. PCC 7002 contains 
almost 20-fold more palmitic acid than stearic acid, with approximately three-fold 
less tetradecanoic acid than stearic acid. No shorter fatty acids were reported 
(29). It has also been shown on multiple occasions that only 19 carbon long 
olefins are produced (3,29,64), indicating the olefin synthase strongly selects 
against the more abundant palmitic acid. Fatty acids shorter than palmitic acid 
are either not present or in low abundance so there is little pressure to select 
against them. This is consistent with the results presented here showing that 
Asp199 creates a negatively charged patch near the C16 position of fatty acids to 
select against palmitic acid (Figure 2.7A). The presence of the charged patch 
may also explain previous work showing that feeding pentadecanoic acid to 
Synechococcus sp. PCC 7002 did not result in 1-hexadecene production (3).  
 
The SynFAAL/A229I variant was originally created with the expectation that it 
would fill the bottom of the binding tunnel and prevent stearic acid from binding, 
but not affect the usage of other fatty acids. Because of the slight movement of 
loops making up the bottom of the binding tunnel, the added bulk of the 
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isoleucine did not significantly decrease the size of the tunnel (Figure 2.7D). The 
mutation did increase the hydrophobicity of the tunnel which resulted in 
increased in palmitic acid usage, further supporting the use of an electrostatic 
selection mechanism. The competing factors of increased hydrophobicity and 
tunnel constriction apparently offset resulting in stearic acid activity similar to WT.  
 
Phe197 and Gly219 are both located close to the C12 position of fatty acids and 
it was expected that replacing either with bulkier side chains would block the 
usage of fatty acids longer than 12 carbons. Both SynFAAL/F197W and 
SynFAAL/G219D variants behaved as expected (Figure 2.8). The 
SynFAAL/F197W variant also caused a slight increase in octanoic acid activity. 
The ideal length of olefins for biofuels applications is 11-15 carbons long; this 
length provides a suitable balance of energy density and melting temperature 
(31). The SynFAAL/G219D variant is highly selective for decanoic acid, which 
would produce 1-undecene. This demonstrates the feasibility of engineering the 
SynFAAL enzyme for the production of specific α-olefins. With additional 
experiments it may be possible to produce SynFAAL variants with high specificity 
for a variety of fatty acid chain-lengths. However, for the production of short α-
olefins it could be more efficient to exchange the entire FAAL domain for one that 
natively works on shorter fatty acids, such as JamA (25). 
 
Met215 is near the C6 position of fatty acids and its replacement with Tyr was 
expected to occlude the binding tunnel. However, experiments showed that only 
 39  
the utilization of long chain fatty acids was affected (Figure 2.8E). My current 
hypothesis is that the tyrosine does not position itself in the binding tunnel, but 
rotates 180° about the Cα-Cβ bond to occupy space to the left of the methionine 
position seen in Figure 2.8C. Consequently, the fatty acid chain would not need 
to adopt the curved confirmation around Met215 and would take a more direct 
path to the bottom of the binding tunnel. The more direct path would cause 
stearic acid to clash with the bottom of the tunnel, leading to the sharp decrease 
in activity. Attempts to crystallized a SynFAAL/R336A/M215Y double variant to 
test this hypothesis did not produce crystals of sufficient diffraction quality. The 
SynFAAL/M215Y/F197W double variant had no detectable activity, and we 
speculate that the additional Trp caused the tyrosine to adopt a tunnel occluding 
conformation.  
 
It was found during in vivo characterization that the Synechococcus sp. PCC 
7002 olefin synthase is involved in the production of a second olefin product, 
1,14-nonadecadiene (3). Subsequent studies indicate that the olefin synthase is 
likely utilizing the desaturated fatty acid C18:1 (Δ13) as the starting fatty acid 
(30). The triangular bulge near the C-12 position of the stearoyl chain appear to 
be able to accommodate a cis-double bonded fatty acid chain (Figure 2.5C).  
 
Moving forward it will be important to examine the variants which modulate 
substrate selectivity in the context of the entire olefin synthase pathway. It has 
been shown that the sulfotransferase is functional on shorter substrates (32), but 
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it is unknown how well shorter substrate will be tolerated by the remainder of the 
olefin synthase. It is tempting to speculate that the remaining olefin synthase 
enzymes do not have selection mechanisms for substrate length and engineering 
would be straightforward; however, future efforts will need to be made to 
examine this possibility. Currently the production of α-olefins for biofuels and 
industrial applications by biological means shows potential. 
 
2.6  Methods and Materials 
2.6.1 Cloning and Mutagenesis 
Synthetic DNAs encoding the SynFAAL (amino acids 2-570) and SynACP1 
(amino acids 600-677) regions of Synechococcus sp. PCC 7002 olefin synthase 
were purchased from IDT. Expression plasmids pMCSG9-SynFAAL and 
pMCSG7-SynACP1 were created by insertion into the pMCSG9 and pMCSG7 
vectors, respectively, and verified by sequencing. SynFAAL variants were 
generated using the QuikChange Lighting kit (Agilent) according to the vendor’s 
directions. Primers were designed using the Agilent QuikChange Primer Design 
tool.   
 
2.6.2 Bacterial strains, media and culture conditions 
Cultures were grown in Terrific Broth (TB) medium with 4% glycerol and 
ampicillin (100 μg/mL). E. coli strain BAP1 (65) was transformed with pMCSG7-
synACP, and strain BL21(DE3) was transformed with pMCSG9-synFAAL.  
Cultures were grown at 37°C in 500 mL TB to an OD600 of 1.5, cooled to 20°C for 
 41  
at least 1 hr, induced with IPTG (final concentration 0.2 mM), and grown for an 
additional 14-18 hr before harvesting by centrifugation. Cell pellets were stored at 
-20°C until used for protein purification.   
 
2.6.3 Purification of wild type SynFAAL and SynFAAL Variants  
Cell pellets were resuspended in approximately 5 mL Buffer A (100 mM Tris pH 
7.5, 300 mM NaCl, 5% glycerol) containing 15 mM imidazole per 1 g cell paste. 
All purification steps were performed at 4°C. Resuspended cells were incubated 
with DNase (4 mg), lysozyme (10 mg), and MgCl2 (4 mM) for 30 min, then lysed 
by three passes though an Avestin EmulsiFlex-C3 homogenizer and clarified by 
centrifugation at 30,000 x g. The soluble fraction was loaded onto a 5-mL 
HisTrap Ni NTA column (GE Healthcare) in Buffer A and eluted with an imidazole 
gradient from 30-300 mM. The eluted protein was treated overnight at 4°C with 
tobacco etch virus (TEV) protease (1:30 ratio TEV:SynFAAL plus 2 mM DTT) to 
remove the purification (polyhistidine) and solubility (maltose binding protein) 
tags, dialyzed into Buffer B (50 mM Tris pH 7.5, 150 mM NaCl, 2.5% glycerol), 
and applied to a 5-mL HisTrap Ni NTA column. The flow-through fraction was 
further purified by size exclusion chromatography with a HiLoad 16/600 
Superdex 200 column (GE Healthcare) in Buffer B.  The FAAL eluted as a 
monomer of apparent molecular weight 51 kDa, and yielded 100 mg of purified 
protein from 500 mL E. coli culture. The protein was concentrated to 20 mg/mL, 
flash cooled with liquid N2, and stored at -80°C.  
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2.6.4 Purification of SynACP1 
SynACP1 was purified identically to SynFAAL except the buffer for purification by 
metal affinity chromatography was 100 mM Tris pH 7.5, 500 mM NaCl, 10% 
glycerol, 5 mM TCEP and the polyhistidine tag was not cleaved. In order to 
ensure full phosphopantetheinylation, SynACP1 was incubated for 16 hr at 30°C 
with the nonspecific phosphopantetheinyl transferase Sfp (66) at a 1:40 ratio in a 
reaction mix also containing 16 mM ATP, 4 mM pantethine, 4 mM DDT, and 0.2 
mg/mL each of CoaA, CoaD, and CoaE (67). Holo-SynACP1 was purified from 
the reaction mix using a HiLoad 16/600 Superdex 75 column (GE Healthcare) 
equilibrated with 100 mM Tris pH 7.5, 250 mM NaCl, 5% glycerol, 5 mM TCEP. 




Prior to crystallization, 5 mg/mL wild type SynFAAL was treated with 10 mM ATP 
and 0.4 mM MgCl2; SynFAAL/R336A and SynFAAL/R336A/A229I with 0.4 mM 
each of ATP, MgCl2, and fatty acid (dissolved in ethanol). Protein solutions were 
clarified by centrifugation at 20,000 x g for 30 min at 4°C. Crystals grew in 3 days  
to two weeks at 20°C by vapor diffusion in 1.8 μL sitting drops containing 0.6 μL 
protein stock and 1.2 μL reservoir solution (0.17-0.21 M NDSB-256, 26-33% PEG 
3350, 0.19-0.21 M ammonium acetate, 0.1M sodium acetate pH 5.5). Crystals 
were harvested in nylon loops and flash cooled in liquid N2. 
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2.6.6 Diffraction Data Collection and Structure Determination 
Diffraction data were collected at 100 K on GM/CA beamline 23ID-D or 23ID-B at 
the Advanced Photon Source (APS) at Argonne National Laboratory (Argonne, 
IL). For each crystal, 360º of data were collected using 0.2º rotation and 0.2 sec 
exposure per image. Data were processed using XDS (68) (Table 2.1). The 
structure of SynFAAL with bound AMP was solved by molecular replacement 
(MR) with Phaser (69) in the PHENIX software suite (70) from the structure of the 
L. pneumophila fatty acyl-adenylate ligase (20) (43% identity, PDB code: 3LNV) 
with the C-terminal domain removed. The initial MR model was expanded using 
AutoBuild (71) to generate a 77% complete model of SynFAAL, and the 
remaining portions of the structure were completed manually using Coot (72). 
Refinement was performed using phenix.refine (73). The structure of 
SynFAAL/R336A/A229I was solved by difference Fourier methods as the crystals 
were isomorphous. SynFAAL/R336A with stearoyl adenylate bound was not 
isomorphous and was solved by molecular replacement using the SynFAAL-AMP 
complex as a search model. Restraints for fatty acyl adenylates were generated 
with eLBOW (74). The structure (Table 1) is complete except for residues 359-
362. Buried surface area was analyzed with PISA (75).  Sequence alignments 
were created with Jalview (76,77) using Clustal O (78). Electrostatic surface 
potentials were calculated with the PDB2PQR server (79,80). Structures were 
validated with MolProbity (81). Images and figures were prepared using PyMOL 
(82). 
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2.6.7 Malachite Green Assay 
Catalytic activity of wild type and variant SynFAAL was determined using an end-
point colorimetric assay coupled to pyrophosphatase (61). All assays were 
performed in 48-well PCR plates. A master mix consisting of reaction buffer (50 
mM Tris pH 7.8, 100 mM NaCl, 10 mM MgCl2), 200 μM ATP, 0.1 U/mL inorganic 
pyrophosphatase (New England Biolab), 20 μM SynACP1, and 1 μM SynFAAL 
was prepared on ice and kept as cool as possible during subsequent steps. 39.2 
μL of master mix was added to wells. 0.8 μL fatty acid dissolved in ethanol was 
then added to the reaction (final concentrations 20 μM fatty acid, 2% ethanol). 
Plates were placed in a thermocycler and incubated at 30°C for 30 min and then 
cooled to 4°C. 33 μL reaction mixture was then transferred to a 96 well reaction 
plate containing 66 μL reaction buffer. Reactions were developed by the addition 
of 20 μL molybdate/malachite green reagent. The released Pi concentration was 
determined at 620 nm on a Molecular Devices SpectraMax M5 384 variable 
wavelength spectrometer. End-point data was used to calculated the initial rate of 
reaction. Reactions were performed in triplicate and repeated at least twice. At 
least one replicate was performed at a different concentration with data 
normalized to 1 μM SynFAAL. For variants with reaction rates similar to WT, 
replicates were performed at a concentration of 0.5 μM SynFAAL and run for 30 
min. For variants with slow reaction rates, replicates were performed at a 
concentration of 2 μM SynFAAL and run for 60 min. Reactions without SynFAAL, 
SynACP1, or fatty acid added were used as negative controls. Absorbance 
measurements were converted to Pi concentrations using a Pi standard curve 
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from 0-25 μM. The 30 min end-point was chosen based on previous experiments 
establishing that the reaction was linear under those conditions (Figure 2.9). 
Briefly, WT SynFAAL was incubated with stearic acid under the same reactions 
conditions used for end-point assays. Time points were taken at 0, 5, 10, 15, 20, 
25, 30, 35, 40, 50, and 60 min. For each time point, 33 μL reaction mixture was 
quenched with 66 μL reaction buffer plus 10 μL formic acid. Once all time points 
were collected, reactions were developed and quantified the same as end-point 
assays. 
 
2.6.8 Detection of FAAL products by HPLC/MS 
30 μL reaction mixtures consisted of 50 mM Tris pH 7.5, 50 mM NaCl, 10 mM 
MgCl2, 5 mM TCEP, 10 mM ATP, 10 μM SynFAAL, and 50 μM holo-SynACP1. 
Reactions were initiated by the addition of 500 μM fatty acid substrate in ethanol 
(final concentration 0.5% ethanol) and incubated at 20°C for 18 hr. A reaction 
mixture without SynFAAL was used as a negative control. 15 μL of reaction 
mixture was injected onto an Agilent 1290 HPLC system after incubation. 
Samples were analyzed by RP-HPLC (Jupiter 5μ C4 column 300Å, 250 X 2.00 
mm) with a 20 min gradient of 30-90% acetonitrile with 0.2% trifluoroacetic acid 
at a flow rate of 0.2 mL/min, peak fractions were collected for LC/MS analysis. 
Peak fractions analyzed by intact protein and phosphopantetheine ejection (83) 
on an Agilent 6520 Q-TOF mass spectrometer equipped with an Agilent 1290 
HPLC system. Samples were separated for MS analysis by RP-HPLC (Aeris 
widepore C4 column 3.6 μm 50 x 2.10 mm) with a 10 min gradient of 10-95% 
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acetonitrile with 0.1% formic acid at a flow rate of 0.5 mL/min. Intact protein and 
phosphopantetheine data were analyzed using the Agilent Mass Hunter 
Qualitative Analysis software with the maximum entropy deconvolution algorithm. 
 
 
Figure 2.9  Linearity of SynFAAL reactions. 
  
WT SynFAAL was incubated with SynACP and stearic acid at the same 
concentrations used for end-point malachite green assays. 11 time points 
taken over 1 hr and quantified using the malachite green reagent. Time course 
was fit using linear regression (R2 = 0.986). The linearity indicated that the 






Table 2.2  End-point initial velocities (μM/min) from malachite green assay. 
 
 
Wild Type F197W D199A D199L G205F 
C4 0.036 ± 0.009 0.02 ± 0.01 0.03 ± 0.02 0.04 ± 0.01 0.01 ± 0.01 
C6 0.031 ± 0.009 0.015 ± 0.004 0.017 ± 0.007 0.038 ± 0.008 0.005 ± 0.004 
C8 0.081 ± 0.009 0.123 ± 0.008 0.08 ± 0.01 0.040 ± 0.007 0.004 ± 0.002 
C10 0.53 ± 0.04 0.097 ± 0.010 0.70 ± 0.04 0.40 ± 0.10 0.004 ± 0.004 
C12 0.49 ± 0.07 0.019 ± 0.003 0.65 ± 0.09 0.64 ± 0.08 0.00 ± 0.003 
C14 0.32 ± 0.04 0.008 ± 0.008 0.39 ± 0.04 0.49 ± 0.06 0.00 ± 0.005 
C16 0.085 ± 0.009 0.02 ± 0.02 0.19 ± 0.05 0.19 ± 0.03 0.00 ± 0.005 
C18 0.22 ± 0.03 0.012 ± 0.003 0.32 ± 0.02 0.31 ± 0.06 0.00 ± 0.006 
C20 0.054 ± 0.007 0.01 ± 0.01 0.05 ± 0.02 0.06 ± 0.01 0.00 ± 0.006 
NFC 0.03 ± 0.01 0.009 ± 0.008 0.02 ± 0.01 0.037 ± 0.008 0.004 ± 0.004 
NEC 0.00 ± 0.005 0.00 ± 0.0007 0.000 ± 0.004 0.000 ± 0.007 0.00 ± 0.005 
NAC 0.004 ± 0.005 0.008 ± 0.006 0.03 ± 0.02 0.029 ± 0.005 0.00 ± 0.008 
      
 
M215Y G219D A229I R336A F197W+M215Y 
C4 0.03 ± 0.01 0.011 ± 0.003 0.041 ± 0.003 0.024 ± 0.003 0.004 ± 0.002 
C6 0.03 ± 0.01 0.009 ± 0.004 0.038 ± 0.006 0.021 ± 0.003 0.005 ± 0.002 
C8 0.12 ± 0.02 0.040 ± 0.008 0.20 ± 0.01 0.10 ± 0.03 0.005 ± 0.001 
C10 0.59 ± 0.05 0.17 ± 0.02 0.71 ± 0.05 0.70 ± 0.05 0.005 ± 0.003 
C12 0.38 ± 0.04 0.028 ± 0.004 0.61 ± 0.02 0.69 ± 0.08 0.004 ± 0.002 
C14 0.26 ± 0.04 0.006 ± 0.007 0.243 ± 0.007 0.34 ± 0.06 0.001 ± 0.003 
C16 0.14 ± 0.03 0.009 ± 0.006 0.24 ± 0.06 0.09 ± 0.01 0.004 ± 0.002 
C18 0.03 ± 0.02 0.010 ± 0.004 0.19 ± 0.04 0.28 ± 0.08 0.002 ± 0.002 
C20 0.023 ± 0.006 0.012 ± 0.003 0.046 ± 0.006 0.05 ± 0.01 0.0037 ± 0.0007 
NFC 0.020 ± 0.008 0.010 ± 0.004 0.034 ± 0.007 0.014 ± 0.005 0.004 ± 0.003 
NEC 0.00 ± 0.002 0.00 ± 0.0005 0.00 ± 0.006 0.00 ± 0.003 0.00 ± 0.003 
NAC 0.005 ± 0.006 0.01 ± 0.001 0.025 ± 0.008 0.019 ± 0.006 0.00 ± 0.005 
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CHAPTER III 
 
Biochemical and Structural Basis for the Functional Divergence of the 
AMP-ligase CahJ in the Cahuitamycin Biosynthetic Pathway 
 
3.1  Notes 
This chapter is being prepared for publication in a manuscript titled "Biochemical 
and Structural Basis for the Functional Divergence of AMP-ligase CahJ in the 
Cahuitamycin Biosynthetic Pathway" with the authors: Tripathi A*, Park SR*, 
Sikkema AP*, Wu J, Cho H, Xi C, Smith JL, Sherman DH. 
*These authors contributed equally to this work. 
 
Author Contributions: 
A.P.S. solved crystal structures of CahJ and performed ArCP loading 
experiments. S.R.P. cloned CahJ and performed malachite green assays. A.T. 
performed mutasynthesis experiments and determined the structure of 
cahuitamycin F. J.W. performed biofilm assays. A.P.S. and A.T. wrote the 
manuscript. A.P.S., A.T., J.L.S., and D.H.S. edited the manuscript. 
 
3.2  Abstract 
Cahuitamycins are potent biofilm inhibitors biosynthesized by a unique bifurcated 
nonribosomal peptide synthetase (NRPS) pathway in Streptomyces 
gandocaensis. Previous in silico analysis and chemical complementation studies 
suggested that an adenylation (A) domain, CahJ, acts as a gatekeeper enzyme 
for cahuitamycin structural diversification. On the basis of this observation, the 
innate substrate flexibility of CahJ was analyzed using an adenylation assay and 
structural characterization of CahJ in complexes containing both native and non-
native substrates. The analysis also led to isolation of a new cahuitamycin 
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congener through targeted precursor incorporation resulting in production of a 
potent Acinetobacter baumannii biofilm inhibitor. The findings represent an 
effective synthetic biology approach to expand the chemical diversity of novel 
anti-biofilm molecules. 
 
3.3  Introduction 
Nature has traditionally served as a prolific source of drug leads for infectious 
diseases and other illnesses (1). Some of the most therapeutically important and 
best-understood natural products are nonribosomal peptides (NRPs). These 
molecules are produced by large multienzyme complexes called nonribosomal 
peptide synthetases (NRPS) (14,84). NRPSs are typically composed of repeating 
enzyme domains that activate and incorporate specific building blocks into a 
growing peptide chain. In general, each module of a traditional NRPS contains 
an adenylation (A), a peptidyl carrier protein (PCP, also known as a thiolation or 
“T” domain) and a condensation (C) domain. NRPSs assemble their peptide 
products through the multienzyme thiotemplate mechanism (14,84,85), in which 
an A domain selects and activates an amino acid substrate via ATP-dependent 
hydrolysis as an aminoacyl-adenylate. The reactive intermediate is then 
transferred to the free thiol group of the 4'-phosphopantetheinyl group on an 
adjacent PCP domain, releasing AMP. In peptide elongation, the upstream 
peptidyl-S-PCP and the free amino group of the downstream aminoacyl-S-PCP 
establish a peptide bond, catalyzed by the C-domain. Variations in the 
architecture of NRPSs can be introduced via any step involving initiation, 
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elongation and termination. The structural diversity of NRPs can also be 
expanded by additional, optional domains that tailor individual building blocks, for 
example an epimerization (E) domain. Several studies over the past two decades 
have shown that NRPS monomer choices are not limited to the 20 proteinogenic 
amino acids. Many different monomers, including nonproteinogenic amino acids, 
fatty acids, aryl acids, and hydroxy acids, have been involved in NRP 
biosynthesis (86). These nonproteinogenic building blocks offer potential for 
structural diversification of NRPs and are likely responsible for their biological 
activity (87).  
 
Cahuitamycins, produced by Streptomyces gandocaensis, are a novel structural 
class that has potent anti-biofilm activity against the Gram-negative pathogenic 
bacterium, Acinetobacter baumannii (2). This multidrug-resistant microorganism 
is responsible for a large number of nosocomial infections, including pneumonia, 
Figure 3.1  Proposed biosynthesis of cahuitamycins A-C in S. gandocaensis.  
 
The CahJ-dependent adenylation of salicylic acid and 6-methylsalicylic acid in 
cahuitamycin assembly is an ATP-dependent process that leads to the release 
of pyrophosphate (PPi). C, condensation domain; Cy, cyclization domain; E, 
epimerization domain T, thiolation domain. 
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urinary tract infections, wound infections, and bacteremia with significantly high 
mortality rates (~60%). Biofilm formation contributes to the pathogen’s high rates 
of antibiotic resistance (88). When in a biofilm, bacteria develop antibiotic 
resistance up to 1,000 fold greater than planktonic forms. Despite the significant 
role of biofilms in infectious diseases, there are currently no drugs that 
specifically target biofilms in clinical use or in clinical trials (1). The generation of 
structurally diverse cahuitamycin analogs could therefore facilitate efforts to 
develop promising anti-biofilm drug candidates for future pharmaceutical 
applications. Understanding cahuitamycin biosynthesis represents a critical first 
step toward the generation of more potent and selective drug analogs. Based on 
previous studies (2), the discrete A domain CahJ could represent an ideal 
avenue to exploit biosynthesis and create new cahuitamycin congeners. 
Cahuitamycin structural variants originate at the loading module, CahJ, which is 
a discrete aryl-AMP ligase, in a process that is analogous to yersiniabactin (89) 
and pyochelin (90) biosynthesis. CahJ is responsible for the selection of an 
appropriate aryl acid substrate and acts as the initial gatekeeper in cahuitamycin 
NRPS assembly (Figure 3.1). A deletion mutant of cahI (ΔcahI), which encodes a 
salicylate synthase, exclusively produced cahuitamycin C while the production of 
cahuitamycins A and B was completely abolished (2). This result confirmed the 
substrate selectivity of CahJ, which is able to utilize two different substrates, 
salicylic acid (SA) and 6-methlysalicylic acid (6-MSA), leading to formation of 
cahuitamycins A, B and C, respectively (Figure 3.1). These initial observations 
are expanded to provide a detailed biochemical analysis of CahJ and its 
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substrate scope, which revealed new opportunities to generate unnatural 
cahuitamycin analogs. The structure of CahJ in complex with both native and 
non-native substrates provided a rational explanation of the substrate scope. 
Lastly, these findings are translated towards generation of novel congeners of 
cahuitamycins.  
 
3.4  Results and Discussion 
3.4.1 Bioinformatics Analysis of CahJ 
Based on the central role of starter unit selection in cahuitamycin diversification 
and biological activity, this study focused on CahJ, a member of the adenylate-
forming enzyme superfamily that clades with the NRPS A domain subgroup (16). 
CahJ has the highest overall amino acid sequence similarity to a salicylate-AMP 
ligase MycE from Sorangium cellulosum So ce56 (91). In silico analysis using 
SMART (92) showed CahJ has an AMP-binding domain spanning residues 31-
437. The closest homolog of known structure is DhbE (58% identity, PDB ID: 
1MD9) (93), which activates 2,3-dihydroxybenozic acid (DHB) (Figure A.1). 
 
3.4.2 Colorimetric Determination of CahJ Enzyme Activity 
While most A domains are selective for a specific substrate, many also have the 
ability to adenylate a range of compounds (94,95). In an effort to investigate 
CahJ specificity toward acyl-substrates, we employed a nonradioactive high-
throughput malachite green colorimetric assay (61). In this system, inorganic 
pyrophosphatase is coupled to a malachite green assay to measure the 
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concentration of orthophosphate (Pi) converted from pyrophosphate (PPi) 
produced during aminoacyl-AMP formation by the A domain. The 59-kDa CahJ 
protein from S. gandocaensis was heterologously expressed in E. coli in an N-
terminal His6-tagged form to conduct the colorimetric assay. Soluble CahJ was 
obtained after Ni(II)-NTA affinity chromatography, followed by desalting prior to 
the enzyme assay (Figure A.2). SA and 6-MSA were tested to confirm their role 
as subunits in biosynthesis of cahuitamycins A-C. Compared with the control 
sample, the adenylation of SA by CahJ led to a high level of color conversion of 
malachite green reagent. 6-MSA also led to a comparable color conversion of the 
malachite reagent (Figure A.2). 
 
3.4.3 Determination of Kinetic Parameters (kcat and Km) 
The previous assay indicated that CahJ possesses an innate ability to catalyze 
activation of both SA and 6-MSA for loading onto the N-terminal CahA PCP, 
more specifically known as an aryl carrier protein (ArCP). Using this assay, 
steady-state kinetic parameters were determined by monitoring the release of PPi 
by the adenylation reaction. The data for SA and 6-MSA were fit using the 
Michaelis-Menten equation (Figure 3.2). SA had a pseudo-Km of 3.5 ± 0.3 μM 
and pseudo-kcat of 0.107 ± 0.002 min
-1, while 6-MSA had a similar but slightly 
lower pseudo-Km and pseudo-kcat (pseudo-Km of 1.6 ± 0.2 μM and pseudo-kcat of 
0.079 ± 0.002 min-1). This observation established the importance of the 2-
hydroxy group over 2-hydroxy-6-methyl group for catalytic efficiency. 
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Interestingly, the efficiency of CahJ in the malachite-green-based assay was 
~1000 fold less than that of its closest structural and functional homologs in 
radiolabel-based assays of the reverse reaction (96-98). This may be due to co-
purification of CahJ with tightly bound salicyl adenylate, as discovered during 
crystallographic studies where the adenylate was retained through multiple 
purification steps and was a major technical hurdle in obtaining crystal structures 
of other substrate complexes. Ultimately, ligand-free CahJ was obtained by 
partial denaturation with urea. E. coli does not encode a salicylate synthase 
based on current genome annotation, and thus the source of the salicylate was 
likely the rich growth media. Growth of E. coli on defined media resulted in co-
purification with benzoyl adenylate. Turnover in the malachite green assay 
coupled to pyrophosphatase requires dissociation of the adenylate, which is 
clearly very slow.  
Figure 3.2  Determination of kinetic parameters of CahJ.  
 
Steady-state kinetic data fit using the Michaelis-Menten equation to determine 
kinetic constants of CahJ for (A) SA and (B) 6-MSA. 
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3.4.4 Substrate Flexibility of CahJ toward Unnatural Substrates  
The previous observation that CahJ activates both 6-MSA and SA (2) and the 
steady state kinetic analysis motivated tests of the ability of CahJ to catalyze 
adenylation of 32 structurally related benzoic acid substrates. As expected, CahJ 
exhibited 73% activity with 6-MSA relative to SA. Similarly, methylated SA 
derivatives, such as 4-methyl-SA (4-MSA) and 5-methyl-SA (5-MSA), showed 
similar activity by CahJ with the exception of 3-methyl-SA (Figure 3.3). However, 
replacing the hydroxyl group at the C2 position of salicylic acid to test the ability 
of CahJ to catalyze adenylation of benzoic acid substrates bearing nitro or acetyl 
functional groups abolished CahJ activity, as evidenced by 2-nitrobenzoic acid, 
acetyl salicylic acid, 4-methyl-2-nitrobenzoic acid, 5-methyl-2-nitrobenzoic acid, 
and 2-methyl-6-nitrobenzoic acid (Figure 3.3). Only 3-methyl-2-nitrobenzoic acid 
served as a CahJ substrate, albeit with relatively low (26%) conversion (Figure 
3.3). Interestingly, halogenated benzoic acid substrates with chlorine/fluorine as 
a substitute for the 2-hydroxyl group and DHB displayed appreciable reaction 
turnover with CahJ. By contrast, CahJ showed no significant activity against 
substrates with extended ring systems (2-(4-chlorophenyl)-1,3-thiazolidine-4-
carboxylic acid, 3-(2-hydroxyphenyl) propionic acid, etc.) or five membered ring 
structures (1,2,4-triazole-3-carboxylic acid, etc.). These observations can be 






Figure 3.3  Determination of CahJ substrate specificity toward diverse benzoic acid substrates.  
 
Relative substrate specificity of CahJ for 30 benzoic acid analogs is represented by the bars. The activity obtained from 
the reaction with SA is defined as 100%. 
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3.4.5 CahJ Loading of CahA ArCP 
The ability of CahJ to transfer SA and 6-MSA onto its natural substrate, the CahA 
ArCP, was evaluated with an intact-protein mass spectrometry assay. CahJ 
effectively catalyzed loading of the CahA ArCP with both SA and 6-MSA (Figure 
3.4). The substrate scope study indicated that effective aryl transfer would be 
limited to 5-MSA, 4-MSA, 2-fluorobenzoic acid and DHB in addition to the natural 
SA and 6-MSA substrates. Surprisingly, CahJ transferred all substrates tested to 
the ArCP including 3-methylsalicylate (3-MSA), which was a poor substrate in the 
malachite green assay (Figure 3.3; Figure A.3). Thus, while the fast and 
convenient malachite green assay sensitively discriminates substrate 
preferences, the results of the ArCP-dependent assay suggest that CahJ may act 
in vivo on an even broader range of substrates.  
 
The apparently greater activity with the natural ArCP acceptor is consistent with 
the high affinity of CahJ for aryl adenylate intermediates. Reaction with ArCP 
breaks the adenylate phosphoester bond by phosphoester-thioester exchange, 
releasing AMP and aryl-ArCP from the enzyme whereas turnover in the 
malachite green assay requires dissociation of the adenylate. Taken together the 
assay results and purification behavior indicate that both the nucleotide and aryl 
moieties of the adenylate contribute to high affinity.  
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3.4.6 CahJ Crystal Structure 
For a rational understanding of CahJ substrate selectivity and subsequent ability 
to incorporate unnatural substrates in the cahuitamycin pathway, crystal 
structures of CahJ in several substrate complexes were solved (Table 3.1). The 
CahJ structure is similar to those of other members of the NRPS A domain 
subfamily (17), particularly those that act on benzoic acid derivatives (93,99,100). 
However, the CahJ structure is the first in the class for which salicylic acid is a 
natural substrate. CahJ consists of an N-terminal domain (amino acids 1-429), 
which contains the substrate binding site, and a C-terminal domain (430-544). 
ATP binds at the interface of the N- and C-terminal domains (Figure 3.5A). The 
C-terminal domain of related enzymes is known to move during the two-step 
Figure 3.4  Intact protein mass spectra of CahJ loading of SA and 6-MSA onto 
CahA ArCP.  
 
CahJ was incubated 1 hr with either SA or 6-MSA and ArCP, in both cases 
leading to complete conversion of holo-ArCP to aryl-ArCP. NEC is a no 
enzyme control. Calculated and observed masses for ionized species are 
listed in Table A.1. 
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reaction, adopting one conformation for the adenylation reaction and another for 
the aryl transfer reaction (101). The C-terminal domain of CahJ occupies the aryl-
transfer conformation in the structures.  
 
3.4.7 CahJ Substrate Binding Site 
CahJ binds aryl substrates in a flat, hydrophobic site between the Phe237 side 
chain and the Gly332-Met333 peptide. The site is ideally shaped to 
accommodate aromatic rings with Phe237 forming offset -stacking interactions 
with the substrate aromatic ring (Figure 3.5B). The narrow shape of the binding 
site dictates that only aromatic, and therefore flat, substrates can be 
accommodated. The periphery of the binding site can be defined as a number of 
pockets corresponding to the positions of the aromatic ring (Figure 3.5D, Figure 
A.4).  
 
The 2 position pocket is formed by Asn236, which forms a hydrogen bond with 
the salicylate 2-hydroxyl. Asn236 is invariant in SA and DHB-utilizing enzymes 
and forms the only hydrogen bond between aryl substrates and CahJ. Lack of a 
2-hydroxyl group decreased activity, for example with 2-fluorobenzoic acid 
(Figure 3.3). The 3 position pocket is defined by the side chains of Cys241 and 
Leu338. The side chains form a steric block that restricts the binding of 
substrates with a substituent at the 3 position as evidenced by the low activity of 






Table 3.1  Protein production and crystal growth conditions plus data collection and refinement statistics for CahJ 
structures. 









CahJ production Rich media, 
urea treatment 




Minimal media Rich media, 
urea 
treatment 
Added ligands AMP, SA none ATP, 5-MSA ATP, 6-MSA none AMP 
Data Collection       
Space group P3221 P3221 P3221 P3221 P3221 P3221 
Cell dimensions a 
and b,c (Å) 
122.1, 87.7 122.4, 88.1 122.0, 87.7 122.2, 88.2 121.7, 87.9 122.0, 88.0 
X-ray source APS 23ID-D APS 23ID-D APS 23ID-D APS 23ID-D APS 23ID-D APS 23ID-D 
Wavelength (Å) 1.033 1.033 1.033 1.033 1.033 1.033 








2.0 (2.12-2.0) 1.78 (1.88-
1.78) 
Rmerge 0.079 (0.955) 0.120 (0.584) 0.097 (1.20) 0.090 (0.822) 0.140 (0.75) 0.098 
(0.777) 
Wilson B factor 24.8 29.6 33.6 31.4 28.6 27.2 
Avg I/σ(I) 20.47 (2.43) 5.86 (1.54) 8.96 (1.19) 10.41 (1.50) 8.35 (1.71) 11.37 (1.76) 
Completeness (%) 99.9 (99.6) 98.9 (98.4) 98.9 (99.2) 99.1 (99.3) 99.4 (99.4) 96.1 (95.1) 
Multiplicity 10.02 (9.71) 3.39 (3.32) 3.40 (3.40) 3.93 (3.84) 3.39 (3.35) 4.06 (4.02) 












CC1/2 0.999 (0.637) 0.985 (0.663) 0.996 (0.414) 0.997 (0.517) 0.986 (0.422) 0.996 
(0.458) 
CC* 0.999 (0.882) 0.996 (0.893) 0.999 (0.765) 0.999 (0.823) 0.996 (0.770) 0.999 
(0.793) 
Refinement       





1Values in parentheses pertain to outermost shell of data. 
 
Reflections used in 
refinement 
109,137 85,969 69,218 72,133 50,752 70,015 
Rwork/Rfree (%) 13.0/16.0 17.4/20.4 15.6/19.3 15.5/19.4 13.8/17.5 14.3/17.5 
Twin fraction 0.29 0.04 0.12 0.17 0.49 0.47 
Non-hydrogen 
atoms 
4,701 5,001 4651 5,025 4,506 4481 
  protein 4,125 4,079 4056 4,083 4,070 4047 
  ligands 43 58 47 68 36 23 
  water 533 864 548 874 400 411 
Amino acid 
residues 
536 537 536 537 536 536 
Deviation from 
ideality 
      
  bond lengths (Å) 0.006 0.007 0.008 0.008 0.007 0.007 
  bond angles (°) 0.84 0.923 0.97 0.84 0.87 0.86 
Average B-factor 
(Å2) 
20.3 27.5 32.1 23.8 23.1 20.3 
  macromolecules 18.4 24.7 30.5 21.2 22.4 19.6 
  ligands 27.0 23.5 29.1 21.3 14.7 17.2 
  solvent 35.3 40.9 44.2 36.1 30.5 27.3 
Ramachandran 
plot 
      
  favored (%) 96.9 97.8 98 97.6 97.0 97.2 
  allowed (%) 2.9 2.0 1.8 2.0 2.8 2.6 
  outliers (%) 0.2 0.2 0.2 0.4 0.2 0.2 
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The 4 position pocket lies between Cys241 and Leu338 and Val330, while the 5 
position pocket is between Val330 and Gly307. The 4 and 5 position pockets are 
both hydrophobic and large enough to accommodate methyl or similarly sized 
substituents. In the 5-MSA adenylate structure, the methyl fits snugly into the 5 
position pocket (Figure 3.5C). In addition, substrates with substituents at either 
the 4 or 5 position had generally high activity in the malachite green assay. Thus, 
it is anticipated that Cl substituent of 3-cholobenzoic acid does not bind in the 
restricted 3 position, but rather occupies the 5 position.  
 
The 6 position pocket is a bounded by invariant Gly307 and Gly308, and is not 
large enough to accommodate a methyl group without a slight rotation (~5°) of 
the aromatic ring, as seen in the 6-MSA adenylate structure (Figure 3.5C). This 
rotation places the 6-methyl substituent close to the 5 position pocket, and would 
Figure 3.5  CahJ structure and substrate binding site.  
 
A) The overall structure of CahJ with the N-terminal domain in green and the 
C-terminal domain in blue. The N- and C-termini are shown as spheres. The 
bound SA adenylate is shown in cyan ball and stick. B) Side view of the flat, 
hydrophobic binding site for the substrate aromatic ring between Phe237 and 
the Gly332-Met333 peptide. The orientations of Phe237 and bound salicyl 
adenylate allow for π-stacking interactions. The protein surface is shown in 
green with the SA adenylate substrate in cyan. C) Overlay of 5-MSA and 6-
MSA adenylates in the CahJ active site. When overlaid, the rotation of 6-MSA 
relative to 5-MSA (and other substrates) is clear. The observed position of 6-
MSA is incompatible with a methyl substituent at the 5 position. D) Face-on 
view of the substrate binding site seen in part B. The 2-hydroxy group forms a 
hydrogen bond with Asn236 (3.0-3.2 Å among the three structures). Pockets 
for the binding of additional substituents are clear at the 4, 5, and 6 positions 
with Val330 creating a separation of the 4 and 5 position pockets. The 3 
position pocket is restricted by Cys241 and Leu338.  
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create a steric clash with Val330 if a 5-methyl substituent were present 
simultaneously This indicates a likely mutually exclusive relationship between the 
two sites. A similar relationship appears to exist between the 4 position and 5 
positions, in which CahJ would accommodate a 4 substituent by a slight rotation 
of the aryl ring. This would result in the binding site poorly accommodating a 5 
substituent. 
 
The CahJ active site is virtually identical to those of family members that act on 
DHB, including DhbE (93), BasE (99) and EntE (100,102). The active sites of all 
four enzymes contain pockets at the 4, 5, and 6 positions of the aromatic ring. 
Other enzymes in the SA/DHB family are expected to possess similar substrate 
flexibility, but only CahJ has been interrogated with a wide panel of substrates. 
EntE possessed substrate promiscuity in tests with two non-natural substrates, 
but neither contained methyl substituents (103).  
 
3.4.8 Expanding the CahJ Active Site  
None of the three substrates induced structural changes to the binding site. The 
stable active site structure may provide an opportunity to engineer the individual 
binding pockets without significantly altering the overall active site structure, 
which may allow further expansion of the substrate range of CahJ and the 
creation of a broader range of cahuitamycin congeners, and ultimately clinically 
efficacious cahuitamycin analogs. The best engineering potential is found at the 
3 position pocket where the Cys241 and Leu338 that form the steric block are 
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naturally variable and are replaced by Ser and Val, respectively, in enzymes that 
act on 2,3-dihydroxybenzoic acid (93). This indicates that amino acid 
substitutions will be well tolerated at these positions, allowing for the removal of 
the steric block and, therefore, activity with substrates containing a 3 substituent 
(Figure A.5B). Val330 restricts the size of substituents at the 4 and 5 positions at 
the bottom of the binding site. Val330 is invariant among enzymes of the 
subfamily, but its replacement with Gly could significantly expand the binding site 
and allow CahJ to accommodate bicyclic ring substrates (Figure A.5C).  
 
3.4.9 Generation of a New Cahuitamycin Analog through a Rational 
Mutasynthesis Approach 
Insights from the biochemical and structural analyses were applied toward 
generation of novel cahuitamycin congeners. The in vitro substrate 4-MSA was 
exogenously introduced to the ΔcahI strain and was incorporated to produce a 
new cahuitamycin analog, cahuitamycin F (1; Figure 3.6). This new metabolite 
was isolated by reverse-phase HPLC (RPHPLC) and the HRESIMS [M+H]+ ion 
peak at m/z 650.2706 provided a molecular formula of C28H39N7O11 (Figure A.6), 
requiring 13° of unsaturation. Extensive 1D and 2D NMR data were acquired for 
1 by Dr. Ashootosh Tripathi and indicated the expected structural similarity with 2 
(Figure 3.6; Table A.2), including 8 methyl/methane carbons, 10 methylene 
carbons and 9 carbonyls/quaternary carbons, similar to the carbon backbone of 
reported cahuitamycins with a clear difference at the phenyl ring system.  
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Figure 3.6  Structures of cahuitamycins F, C and A. 
 
Cahuitamycins F, C and A (1–3) with absolute stereochemistry. Cahuitamycins 
F shows key HMBC and COSY correlations. 
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3.4.10 Biological Activity of cahuitamycin F (1) 
Cahuitamycin F (1) was next tested for its ability to inhibit biofilm formation of A. 
baumannii using crystal violet based static biofilm assay followed by optical 
density measurements. The assay was conducted using cahuitamycin A (3) as a 
positive control and the result from this assay showed that 1 is able to inhibit 
biofilm formation with only a minimal effect on bacterial growth (Figure 3.7). The 
calculated half-maximal inhibitory concentration (IC50) value for 1 was 18.3 µM, 
which is similar to the IC50 of 3 (15.6 µM) against A. baumannii biofilm formation. 
It was previously observed that methylation at the 5 or 6 position of the terminal 
hydroxyphenyl group caused an increase in biofilm inhibition compared to 
cahuitamycin A (3) (2). Methylation at the 4 position causes a slight decrease in 
activity, indicating that the benefits of methylation are position specific. 
Cahuitamycin F (1) showed negligible impact on the growth of A. baumannii, 
consistent with the activity of other cahuitamycins. The data suggest that the 
terminal 2-hydroxybenzoyl-oxazoline group represents a key pharmacophore of 
the cahuitamycins. This insight is important for future medicinal chemistry efforts 
geared toward increasing the efficacy of this new class of natural product biofilm 
inhibitors. 






























































3.5  SIGNIFICANCE 
This study describes the structural and biochemical characterization of CahJ, a 
promiscuous NRPS adenylation domain from Streptomyces gandocaensis. CahJ 
Figure 3.7  Biological activity of cahuitamycins A (3) and F (1).  
 
A) Inhibition of biofilm formation and (B) growth of A. baumannii in the 
presence of cahuitamycins A and F. Results are the average of three 
replicates ± standard deviation. 
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natively selects salicylic acid and 6-methylsalicylic acid as starter units for the 
cahuitamycin biosynthetic pathway. First CahJ steady-state kinetic parameters 
were determined for SA (pseudo-Km of 3.5 ± 0.3 μM, pseudo-kcat of 0.107 ± 0.002 
min-1) and 6-MSA (pseudo-Km of 1.6 ± 0.2 μM, pseudo-kcat of 0.079 ± 0.002    
min-1) (Figure 3.2). It was then demonstrated that CahJ is capable of activating a 
range of benzoic acid derivatives and transferring them to the N-terminal ArCP of 
CahA. The first crystal structures of CahJ complexes with both natural and 
unnatural substrates provided insight to the structural basis of substrate flexibility 
and development of a structure-based explanation of the biochemical data. The 
combined biochemical and structural studies where then used to guide efforts to 
generate new cahuitamycin congeners, leading to the generation of a novel 
cahuitamycin analog, cahuitamycin F, via mutasynthesis. This study also 
provides an effective roadmap for future protein engineering to alter CahJ 
substrate selectivity to generate new clinically efficacious cahuitamycin analogs. 
  
3.6  EXPERIMENTAL PROCEDURES 
3.6.1 General experimental procedures  
Optical rotation measurements were obtained on a Perkin-Elmer 241 Polarimeter 
calibrated using a Rudolph Quartz Control Plate Calibration Standard at sodium 
D line (at +11.502°). Ultraviolet spectra were obtained on a UV-visible Molecular 
Devices SpectraMax M5 spectrophotometer using 1-ml cuvettes with 1.0 cm path 
lengths at room temperature in solvent methanol (MeOH). Spectrophotometric 
assays were performed on Molecular Devices SpectraMax M5 384 variable 
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wavelength spectrometer. All NMR spectra were acquired on a Varian INOVA 
600MHz spectrometer at the NMR Facility, Life Sciences Institute, University of 
Michigan. HRESIMS spectra were measured at the University of Michigan core 
facility in the Department of Chemistry using an Agilent 6520 Q-TOF mass 
spectrometer equipped with an Agilent 1290 HPLC system. RP-HPLC was 
performed using Econosil C18 10 mm 22×250-mm column and Agilent ZORBAX 
RX-C8 5 mm 9.4×250-mm column and a solvent system of MeCN and H2O. The 
LC-MS analysis of HPLC fractions was performed on a Shimadzu 2010 EV APCI 
spectrometer. 
 
3.6.2 Protein Expression, Purification 
 The cahJ gene was amplified by PCR from genomic DNA of S. gandocaensis 
using the primer SR235 (5’-
GCCGCGCGGCAGCCATATGCTCGATGGGTGGGTG-3’) and SR236 (5’-
TCGAGTGCGGCCGCAAGCTTCAGTGGACACCGCCGTC -3’). Cloning of cahJ 
gene into pET28b (Novagen) for expression of N-terminal His6-tagged CahJ was 
performed using Gibson assembly (104) master mix (New England Biolabs). The 
amplified PCR product of cahJ and pET28b, which had been cut by EcoRI and 
HindIII, were incubated at 50°C for 2 h. Following incubation, the samples were 
transformed into E. coli DH5α and isolated. The accuracy of cahJ in pET28b was 
confirmed by restriction digestion and sequencing. Synthetic codon-optimized 
DNA encoding the CahA ArCP was purchased from IDT, inserted into the 
pMCSG7 vector using LIC cloning (105), and verified by sequencing. 
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3.6.3 Protein Expression and Purification  
Recombinant plasmid pET28b-cahJ was utilized to transformed into Escherichia 
coli BL21(DE3)/pRARE cells. The resulting transformant was grown at 37 °C in 1 
liter of LB broth containing kanamycin (50 μg/ml) until OD600 reached 0.6~1.0. 
Then, isopropyl-β-D-thiogalactopyranoside (IPTG) was added to a final 
concentration of 0.2 mM to induce gene expression and cells were cultured at 
18°C overnight. Cells were harvested by centrifugation at 5,000 × g for 10 min at 
4°C to harvest cells. The cell pellet was resuspended in 70 ml of lysis buffer (50 
mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 10% glycerol, 0.1mM EDTA 
(pH8.0), 0.2mM TCEP, pH7.6) and lysed by sonication. Cell debris was removed 
by centrifugation for 20 min at 45,000 × g. The supernantant was mixed with 1 ml 
of Ni-NTA agarose (Qiagen) for 1 h at 4 °C and loaded onto an empty column. 
The column was washed with 50-100 ml of wash buffer (50 mM NaH2PO4, 300 
mM NaCl, 20 mM imidazole, 10% glycerol, 0.2mM TCEP, pH7.6). The bound 
His6-tagged proteins were eluted with elution buffer (50 mM NaH2PO4, 300 mM 
NaCl, 250 mM imidazole, 10% glycerol, 0.2mM TCEP, pH 8.0). The CahJ (59 
kDa) proteins were further purified and concentrated with 30K size exclusion 
filters (Amicon). Buffer exchange with storage buffer (50 mM NaH2PO4, 10% 
glycerol, pH7.3) using a PD-10 column (GE Healthcare) was used to lower the 
sample’s salt concentration. Protein concentration was determined using 
NanoDrop spectrophotometer. The molar extinction coefficient for CahJ at A280 is 
52,370 M-1cm-1. 
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3.6.4 Expression and Purification of CahA ArCP and CahJ for crystallization  
Cultures were grown in either Terrific Broth (TB) medium containing 4% glycerol 
or in M9 minimal medium supplemented with nutrient mix (AthenaES) and L-
methionine (Sigma) as indicated. Ampicillin (100 μg/mL, pMCSG7), 
spectinomycin (50 μg/mL, pRARE), and kanamycin (50 μg/mL, pET28b) were 
used with the corresponding plasmids in E. coli cultures. E. coli strain BAP1 (65) 
was transformed with pMCSG7-cahA_ArCP, and strain BL21-AI (Thermofisher) 
was transformed with pET28b-cahJ. Both strains contained the pRARE plasmid 
(106). Cultures were grown at 37°C in 500 mL TB with 4% glycerol to an OD600 of 
1.5, cooled to 20°C for at least 1 hr, induced with IPTG (final concentration 0.2 
mM), and grown for an additional 14-18 hr before harvesting by centrifugation. 
Cell pellets were stored at -20°C until used for protein purification.  
 
Cell pellets were resuspended in approximately 5 mL Buffer A (50 mM HEPES 
pH 7.6, 250 mM NaCl, 5% glycerol) containing 15 mM imidazole per 1 g cell 
paste. All purification steps were performed at 4°C. Resuspended cells were 
incubated with DNase (4 mg), lysozyme (10 mg), and MgCl2 (4 mM) for 30 min, 
then lysed by three passes through an Avestin EmulsiFlex-C3 homogenizer. The 
lysate was clarified by centrifugation at 30,000xg in a Sorvall F21-8x50y rotor. 
The soluble fraction was filtered through 0.45 μm and 0.22 μm filters and then 
loaded onto a 5-mL HisTrap Ni NTA column (GE Healthcare) and eluted with an 
imidazole gradient up to 300 mM in Buffer A. The eluate was concentrated to 
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approximately 5 mL using a 50 kDa Amicon Ultra-15 membrane, centrifuged at 
20,000xg for 30 min, then loaded onto a HiLoad 16/600 Superdex 200 column 
(GE Healthcare) equilibrated with Buffer B (20 mM Tris pH 7.5, 150 mM NaCl, 
10% glycerol) and isocratically eluted. Fractions were pooled, concentrated as 
above to 20-30 mg/mL, centrifuged at 20,000xg for 30 min, flash frozen in 20-50 
μL aliquots with liquid N2, and stored at -80°C. CahJ co-purified with bound SA 
adenylate from cells grown in rich media and with bound benzoyl adenylate from 
cells grown in minimal media. These co-purifying ligands were removed from 
CahJ by inserting the following steps while the protein was bound to the HisTrap 
Ni NTA column, prior to elution with imidazole: 10 CV linear gradient of 0 to 500 
mM urea in Buffer A; 5 CV wash; 10 CV linear gradient of 500 mM to 0 urea in 
Buffer A containing 1 mM AMP; and 5 CV wash with Buffer A containing 30 mM 
imidazole.  
 
CahA ArCP was purified identically to CahJ except that the buffer was 100 mM 
Tris pH 7.5, 500 mM NaCl, 10% glycerol, 5 mM TCEP. The eluate was 
concentrated using a 10 kDa Amicon Ultra-15 to approximately 10 mg/mL. CahA 
was then incubated for 16 hr at 30°C with the phosphopantetheinyl transferase 
Sfp (66) at a 1:40 ratio in a reaction mix containing 16 mM ATP, 4 mM 
pantethine, 4 mM DDT, and 0.2 mg/mL of CoaA, CoaD, and CoaE (67). After 
incubation, protein was centrifuged at 20,000 xg for 30 min and then loaded onto 
a HiLoad 16/600 Superdex 75 column (GE Healthcare) equilibrated with 100 mM 
Tris pH 7.5, 250 mM NaCl, 5% glycerol, 5 mM TCEP and isocratically eluted. 
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Fractions were pooled, concentrated to 10 mg/mL, centrifuged at 20,000 xg for 
30 min, flash frozen in 20-30 μL aliquots with liquid N2, and stored at -80°C.  
 
3.6.5 Crystallization 
Frozen CahJ stock solution was thawed on ice and glycerol was removed by 
buffer exchange into 20 mM Tris pH 7.5, 150 mM NaCl using a 50K Amicon Ultra 
0.5 membrane. After addition of the appropriate substrates (final concentration 
for all 1.5 mM, Table 3.1), the mixture was diluted to a final concentration of 20 
mg/mL CahJ, incubated on ice for 30 min, and clarified by centrifugation at 
20,000xg for 30 min at 4°C. Crystals grew in approximately one week at 20°C by 
vapor diffusion in 1.5-μL sitting drops containing equal volumes of protein stock 
and reservoir solution (0.08-0.14 M sodium cacodylate pH 6.5, 1.5 - 2.0 M 
sodium acetate). Crystals were harvested in nylon loops, cryoprotected in 
reservoir solution containing 20% glycerol, and flash cooled in liquid N2.  
 
3.6.6 Diffraction Data Collection and Structure Determination 
Diffraction data were collected at 100 K on GM/CA beamline 23ID-D at the 
Advanced Photon Source (APS) at Argonne National Laboratory (Argonne, IL). 
For each crystal, 360º of data were collected at an X-ray energy of 12 keV with 
0.2º rotation and 0.2 sec exposure per image. Data were processed using XDS 
(68). The structure of CahJ with bound AMP and salicylic acid was solved by 
molecular replacement (MR) with Phaser (69) in the PHENIX (70) software suite 
from the DhbE structure (93) (58% identity, PDB code: 1MD9) with the C-terminal 
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domain removed. The initial model from MR was modified with AutoBuild (71) to 
generate a 75% complete model of CahJ. The remaining portion of model was 
completed manually using Coot (72). Refinement was performed using 
phenix.refine (73). Structures of CahJ with other ligands were solved by 
difference Fourier methods as the crystals were isomorphous. Restraints for all 
substrates, except AMP, were generated using eLBOW (74). Images and figures 
were prepared using PyMOL (82). 
 
3.6.7 Determination of Substrate Specificity and Kinetic Parameters 
The substrate selectivity of CahJ was determined using a non-radioactive 
colorimetric assay (61). All assays were performed in 384-well reaction plates. To 
perform the assays, benzoic acid substrates were prepared in DMSO and 10 μl 
was transferred in triplicate to a 384-well reaction plate. Reactions were initiated 
by adding the mixture (40 μl) containing recombinant CahJ (6 μM), inorganic 
pyrophosphatase (0.2 U/ml), ATP (0.5 mM), NaCl (100 mM), MgCl2 (10 mM), 
substrates (20 μM), and 50 mM Tris–HCl (pH 7.5) and incubated at RT. The 
reactions were terminated after 10 min by the addition of molybdate/malachite 
green reagent (10 μl). After 10 min of color development, the released Pi 
concentration was monitored at 600 nm on a microplate reader (SpectraMax®). 
For the determination of Km and kcat for formation of SA adenylate (SA-AMP) and 
6-MSA adenylate (6-MSA-AMP), reactions were done with varying 
concentrations of SA and 6-MSA (1.25 μM, 2.5 μM, 5.0 μM, 10.0 μM, and 20.0 
μM) in the same condition as described above. The reactions were incubated at 
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RT and stopped after 0, 5 and 10 min by the addition of molybdate/malachite 
green reagent (10 μl). A reaction mixture without the recombinant CahJ domain 
was used as a negative control. The experiments were carried out in triplicate for 
each substrate concentration.  
 
3.6.8 CahJ Mass Spectrometry Assays with ArCP 
Reactions in 25 μL mixtures (50 mM Tris pH 7.8, 100 mM NaCl, 10 mM MgCl2, 
500 μM ATP, 2 μM CahJ, and 20 μM ArCP) were initiated by addition of 500 μM 
substrate in DMSO (final concentration 0.5% DMSO), incubated at 25°C for 1 hr, 
quenched by the addition of 10% formic acid, and stored at 4°C prior to analysis. 
1 μL of reaction mixture was used for LC-MS analysis (Agilent 6545 Q-TOF 
equipped with Agilent 1290 HPLC system). Samples were separated for intact 
protein analysis by RP-HPLC (Aeris widepore C4 column 3.6 μM, 50 X 2.10 mm) 
with a 10 min gradient of 10-95% acetonitrile with 0.1% formic acid at a flow rate 
of 0.5 mL/min. Data were analyzed using the Agilent Mass Hunter Qualitative 
Analysis software with the maximum entropy deconvolution algorithm. A reaction 
mixture without CahJ was used as a negative control. 
 
3.6.9 Generation of Cahuitamycin Analog through Mutasynthesis  
Mutant strain of ΔcahI (DHS334) was first pre-cultured in 3ml R2YE liquid 
medium for 15 days at 28 °C and then 3ml of the seed culture was used to 
inoculate 100 ml of the same medium, followed by cultivation for 15 days at 28 
°C. Salicyclic acid (as positive control) and 4-methylsalicylic acid were added 
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every alternate day to separate 100 mL cultures of ΔcahI at a final concentration 
of 500 µM for 10 days. The products were first extracted using Amberlite XAD-
16. The resin was separated and subjected to organic extraction using 
MeOH:EtOAc (1:1) for LC-MS analysis as described above.  
 
The substrate-fed crude extract was then further purified by RP-HPLC on a 
gradient of 10–75% ACN and was followed by ultraviolet–visible photodiode 
array detection at 215 nm to yield semi-pure compounds 1 (4.3 mg). Compounds 
were again subjected to re-purification over RP-HPLC on isocratic condition of 
35% MeOH (0.1% FA) using C-8 column to get compounds 1 (2.1 mg). 
Cahuitamycin F (1). Amorphous powder; ultraviolet (ACN: H2O) λmax 204, 240, 
252 and 304 nm; 1H and 13C NMR, see Table A.2; HRESIMS m/z 650.2706 
[M+H]+ (calculated for C28H40N7O11, 650.2786). 
 
Advanced Marfey’s analysis (107,108) was pursued to ascertain the absolute 
stereochemistry of 1. Acid hydrolysis of cahuitamycin F was conducted followed 
by derivatization with 1-fluoro-2,4-dinitrobenzene-5-alanine amide (FDAA). The 
derivatized product was then analyzed using LC-ESI-MS chromatogram to 
compare m/z 357.27, 382.32 and 400.34 for Ser, Pip and N-OH-Orn (hydrolyzed 
product of N-OH-N-fOrn), respectively. The analysis clearly revealed the absolute 
configuration of the moieties in the hydrolysate of 1 to be L-Ser, L-Ser, D-Pip and 
D-N-OH-Orn, respectively. 
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3.6.10 Minimum Inhibitory Concentration Test  
Cultures of A. baumannii ATCC 17978 grown overnight were diluted into fresh 
10% Mueller Hinton II broth to get 105 colony-forming units per ml by determining 
optical density at OD600. A volume of 100 μl of diluted cultures were incubated in 
individual wells of 96-well plate containing 1% of DMSO and various 
concentrations of cahuitamycins A (3) and F (1). The plate was incubated at 
30°C with shaking at 150 r.p.m. The optical density of each well was monitored 
every 1 hr up to 24 hrs using a microtiter plate reader (Synergy HT, Bio-Tek, 
Winooski, VT) 
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Appendix A 
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Figure A.1  CahJ sequence alignment.  
 
Secondary structure of CahJ shown above alignment. GenBank accession 
codes are as follows: CahJ (AMK48234.1), DhbE (AAN15214.1), BasE 
(AKA30931.1), EntE (ADB98052.1). 














Figure A.2  CahJ purification and activity. 
 
A) Coomassie blue-stained SDS-PAGE gel of CahJ. B) Representative data of 
CahJ activity for SA and 6-MSA by malachite green assay. SA and 6-MSA 
samples show an obvious color change from yellow to green compared to 
control. 
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Figure A.3  Intact protein MS of CahJ loading of unnatural substrates onto 
CahA ArCP.  
 
CahJ was incubated 1 hr with benzoic acid (A), 3-MSA (B), 4-MSA (C), 5-MSA 
(D), or 2-fluorobenzoic acid and ArCP, in all cases there was complete 
conversion of holo-ArCP to substrate loaded ArCP. NEC is a no enzyme 
control. Calculated and observed masses for ion species can be found in 
Table A.1 
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Figure A.4  CahJ substrate interactions. 
 
CahJ interaction with substrate adenylates, generated by LigPlot+ (109).  A) 5-
MSA adenylate. B) 6-MSA adenylate. C) Benzyl adenylate. D) SA adenylate. E) 
Overlay of the four previous LigPlots. Red circles indicate contacts observed in 
multiple substrate complexes.  
 84  
Figure A.5  Engineering potential of the CahJ substrate binding site.  
 
A) The native CahJ binding site with bound SA adenylate (protein in green, SA 
adenylate in cyan). B) EntE binding site with bound DHB analog (100). 
Substitution of CahJ Cys241 with Ser and Leu338 with Val is expected to open 
the 3 position pocket in a similar fashion (protein in orange, substrate in deep 
teal). C) Model of the CahJ substrate binding site with the V330G substitution. 
The replacement opens a significant volume at the 4 and 5 position pockets and 
could accommodate bicyclic rings (protein in forest green, substrate in cyan). 
 
 
























holo-ArCP 12216 12216 
Salicylyl ArCP 12336 12336 
6-MSA ArCP 12350 12350 
Benzyl ArCP 12320 12320 
3-MSA ArCP 12350 12350 
4-MSA ArCP 12350 12350 
5-MSA ArCP 12350 12350 
2-Fluorobenzyl ArCP 12338 12338 
Figure A.6  HRRESIMS [M+H]+ chromatogram of cahuitamycin F (1). 
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Table A.2  NMR spectroscopic data for cahuitamycins F. 
  Cahuitamycin F (1) 
  δC δH, multi (J in Hz) COSY HMBC 
1 174.1       
2 36.5 2.37, m  3 1 
 
  2.41, m 
 
  
3 36.9 3.37, m 2 1 




5 50.8 4.41, dd (4.5, 9.5) 6 4, 9 
6 28.1 1,78, m 5, 7   
    1.98, m 5, 7   
7 20.9 1.92, m 6, 8 5 
    1.99, m 6, 8   
8 52.5 3.57, m 7 9 




10 54.4 4.30, dt (6.0, 14.0) 11 9, 11, 15 
11 29.1 1.62, m 12, 10   
    1.84, m 10   
12 23.5 1.63, m 11, 13 13, 10 
    1.68, m 11, 13 10 
13 51.1 3.43, t (6.4, 13.0) 12 11, 14 
     






16 56.9 4.47, m 17 15, 18 




19 68.9 5.10, dd (7.5, 10.0)  20 18 
20 70.4 4.59, dd (7.5, 9.0) 19 18, 21 







23 129.3 7.58, d (7.0)  24 21, 22, 28 
24 121.6 6.77, d (7.0 23 26, 27 
25 108.6   
 
26 21.3 2.31, s 
 
24, 25, 27 
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Chapter IV 
 
Structural and Biochemical Studies of the Pivalyl- Generating Loading 
Module from the Apratoxin A Biosynthetic Pathway 
 
4.1  Notes 
AprA di-domain acetoacetyl-ACP methylation activity data provided by Meredith 
Skiba. 
 
4.2  Abstract 
Natural products are a source of interesting chemical moieties and novel 
enzymatic reactions. Apratoxin A, from the marine cyanobacterium Moorea 
bouillonii, contains a rare natural t-butyl group, and its creation likely involves 
novel enzymatic reactions. The t-butyl is introduced as part of a pivalyl group by 
the biosynthetic loading module, the AprA protein. By sequence analysis, AprA is 
a GNAT-based loading module. GNAT-based loading modules decarboxylate 
malonyl-CoA and transfer the resulting acetyl group to an associated acyl carrier 
protein (ACP). AprA contains two additional methyltransferase (MT) domains, 
MT1 and MT2, which are proposed to convert the acetyl-ACP to pivalyl-ACP. 
Here, data are presented showing that the AprA loading module diverged from 
other GNAT-based loading modules. A GNAT-MT2 crystal structure reveals that 
the GNAT domain is truncated relative to other GNAT domains and is likely 
vestigial. Biochemical experiments showed that AprA does not possess acyl-CoA 
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decarboxylation activity, but retains acyltransfer activity and preferentially utilizes 
acetyl- and propionyl-CoA as substrates. The ArpA MT2 domain is similar to an 
extension-module C-methyltransferase (CMT) from the curacin A pathway, and 
catalyzes di-methylation of acetoacetyl-ACP. These findings provide a tantalizing 
hint at the in vivo function of AprA and a foundation for future investigations of 
AprA. 
 
4.3  Introduction  
Marine cyanobacteria are a rich source of secondary metabolites with great 
potential for pharmaceutical development (1).  Apratoxin A is a cytotoxic natural 
product of Moorea bouillonii with potent antitumor activity (110,111). It interferes 
with biogenesis of proteins destined for the secretory pathway by blocking 
cotranslational translocation across the endoplasmic reticulum membrane 
through interaction with Sec61, the central subunit of the protein translocation 
channel (5,52,53). Although the total synthesis of apratoxin A has been reported 
(112), its ten chiral centers present a significant challenge to exploration of 
chemical space in the development of derivatives with altered bioactivity (Figure 
4.1). The biosynthetic pathway is thus an attractive target for further 
diversification of this interesting molecule. 
 
Apratoxin A is produced by a hybrid modular polyketide synthase (PKS) / 
nonribosomal peptide synthetase (NRPS) (Figure 4.1) (4). One of the most 
striking chemical features of apratoxin A is a t-butyl group generated by the 
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loading module that initiates biosynthesis, based on biosynthetic gene cluster 
annotation (4) (Figure 4.2). The initiation step is an important source of natural 
product diversity that can proceed though a number of biosynthetic schemes 
(15). The apratoxin loading module consists of the single polypeptide, AprA, 
which belongs to a family of loading modules defined by the presence of a 
GCN5-related N-acetyltransferase (GNAT)-like (hereafter referred to as GNAT) 
domain. Previous work characterized a remarkable dual catalytic activity in the 
GNAT of the curacin A biosynthetic pathway in which malonyl-CoA is 
decarboxylated and the resulting acetyl group is transferred to the loading 
module acyl carrier protein (ACP) (35). GNAT-based loading modules occur in 
secondary metabolite biosynthetic pathways in diverse biological sources 
including uncultured symbionts (44,47,113,114), betaproteobacteria (48,115), 
myxobacteria (49), and cyanobacteria (4,50,51); however, only the curacin A 
loading module has been characterized (35). The GNAT and ACP domains 
constitute the minimal GNAT-based loading module, but many of the 
approximately dozen annotated GNAT-based loading modules contain additional 
domains. The AprA loading module contains three additional domains and has 
the following domain organization: adaptor region (AR) - methyltranferase 1 
(MT1) - GNAT - methyltransferase 2 (MT2) - ACP. 
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The loading-module GNAT domains are presumed to decarboxylate malonyl-
CoA and to transfer acetyl to the adjacent ACP, based on the established activity 
of the CurA GNAT (35) and their high level of sequence conservation (typically 
30-40% sequence identity) (Figure B.3). However, the AprA GNAT is an 
exception, as it has poor sequence conservation (~20% identity to other GNATs, 
Figure 4.1  The apratoxin A biosynthetic pathway.  
 
The domains and products of the pathway modules are color coded: purple 
loading module, orange/gray/pink/red PKS extension modules, blue β-
branching cassette, green NRPS extension modules, and cyan offloading 
module. 
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with several gaps in the alignment) (Figure 4.3; Figure B.3) and appears to lack 
the conserved His and Thr amino acids that are essential to the decarboxylation 
activity of the CurA GNAT (35). This suggests that the AprA GNAT may function 
differently from the other loading module GNATs.   
Figure 4.2  Representative GNAT-based loading modules from four 
biosynthetic pathways.  
 
From left to right: the domain composition of the loading modules, the 
chemical product of the loading module, and location of the loading module 
product, shown in red, in the final natural product structure.  
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Many GNAT-based loading modules contain an AR domain.  Although it is highly 
conserved, the AR domain has no identified function and has no obvious 
homology with any protein of known structure or function. The AR domain is 
proposed to bind the phosphopantetheine (Ppant) cofactor of the ACP and 
facilitate its interaction with the GNAT domain (35). In several loading modules, 
the AR domain is followed by a putative MT domain, (4,49,50,116) based on 
conservation of sequence motifs for type I S-adenosylmethionine (SAM) 
dependant methyltransferases (Figure B.2) (117). Interestingly, while the MT 
domains from the saxitoxin (SxtA) and gephyronic acid (GphF) loading modules 
are ~50% identical (Figure 4.3C), the SxtA MT is proposed to perform a mono-
methylation, whereas feeding studies indicate that the GphF MT performs a di-
methylation (49). The determinants of mono- or di-methylation are unknown.  If 
the AprA GNAT loads acetyl on the AprA ACP, then three methylation reactions 
are needed to generate the t-butyl group. A second methyltransferase domain 
(MT2) following the GNAT is unique to the AprA loading module. MT2 has low 
sequence identity to other loading module MT domains, including AprA MT1 
(Figure 4.3C), and is most closely related to MT domains in PKS extension 
modules. Recent studies showed that these MT domains methylate -keto 
substrates linked to ACP or N-acetylcysteamine (NAC) (118,119) (54). The core 
domains of AprA MT2 and the MT domain from a curacin A extension module 
(CurJ MT), for which the crystal structure was recently reported (54), are 
approximately 40% identical (Figure B.4). 
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Figure 4.3  Bioinformatics analysis of the AprA loading module.  
 
A) Schematic of AprA with estimated domain boundaries shown at top. Solid 
lines indicate high-confidence portions, dashed lines indicate low-confidence 
portions. Domain coloring corresponds to Figure 4.2. Sequence identities to 
loading module domains of other pathways are shown below. The bottom row 
indicates the structure in the PDB with greatest sequence identity to each 
AprA domain. B) Pairwise identity matrix of the GNAT domains shown in A. 
Green indicates a good alignment. Loading module GNAT domains typically 
have ~40%  sequence identity, AprA is an outlier. C) A pairwise identity matrix 
of the MT domains shown in A. Blue indicates a good alignment. See Figures 
B.1 to B.4 for sequence alignments. 
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Among GNAT-type loading modules, the dual MT domains and the truncated 
GNAT are unique to AprA, and may represent a novel biosynthetic loading 
scheme and a novel route to a natural product t-butyl group. Here we present 
investigations of the AprA loading module decarboxylation, acyltransfer, and 
methyltransfer activities as well as the X-ray crystal structure of a GNAT-MT2 di-
domain. 
 
4.4  Results and Discussion 
4.4.1 Bioinformatics Analysis 
Extensive bioinformatics analysis was performed on AprA to assess the function 
of each domain and the boundaries between the 5 domains. A well conserved 
AR domain exists in about half of GNAT-based loading modules, but it is not 
similar to any protein of known structure or function (Figure 4.3A and Figure B.1). 
The MT1 domain is also well conserved among loading modules that contain 
them but has very weak similarity of any MT of known structure (Figure 4.3A and 
Figure B.2). The high sequence conservation of the AR and MT1 domains also 
exists in the linker region, making it difficult to identify the boundaries of the 
domains. The putative AprA GNAT domain has weak similarity to other loading 
module GNAT domains (Figure 4.3A and B), and the C-terminal region is highly 
dissimilar. (Figure B.3). The dissimilarity in the C-terminal half of the GNAT 
domain continues into a poorly conserved region at the N-terminus of MT2. MT2 
has strong similarity to PKS extension module CMT domains, but not other 
loading module MT domains such as MT1 (Figure 4.3C). The alignment of AprA 
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MT2 and PKS CMT domains (Figure B.4) informed the structural study of the 
CurJ CMT as published recently in ACS Chemical Biology (54). The uncertainly 
in the GNAT C-terminal region and the MT2 N-terminal region led to uncertainty 
in the boundary between the GNAT and MT2 domains.  
 
Based on the bioinformatics analysis, a wide screen of AprA variants consisting 
of both individual domains and multidomains was carried out. Ultimately four 
variants were purified; full length AprA, AprA ΔACP, AprA di-domain, and AprA 
ACP (Table B.1). The ΔACP variant consisted of the AR, MT1, GNAT, and MT2 
domains and the di-domain variant consisted of the GNAT and MT2 domains. 
The ACP domain was the only individual domain that could be purified. No 
excision points were identified for production of other single domains. 
 
4.4.2 Decarboxylation Activity of AprA 
To determine if AprA has decarboxylation activity through the use of alternative 
catalytic amino acids, we assessed the ability of the AprA to decarboxylate 
malonyl- and methylmalonyl-CoA. AprA di-domain was incubated with malonyl- 
or methylmalonyl-CoA for 4 hours and quantified by RP-HPLC. Under the 
conditions used, no acetyl- or propionyl-CoA products were detected (Figures 
4.4A and B). The GNAT domain from the CurA loading module was used as a 
positive control and showed complete decarboxylation (Figures 4.4C and D). 
Previously the CurA GNAT was shown to catalyze the decarboxylation of 
malonyl-CoA with a kcat of 1.8 per sec using the same assay (35). Thus, the AprA 
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GNAT is unlikely to be a decarboxylase, consistent with the lack of 
decarboxylase-essential His and Thr amino acids.  
 
4.4.3 Acyltransfer Activity of AprA 
Next, an MS-based assay was developed to test whether AprA possesses 
acyltransfer activity and to determine which acyl-CoA is the preferred substrate.  
AprA ΔACP or di-domain was incubated with AprA ACP and acyl-CoA for 3 hours 
with time points taken approximately every 30 min. Reactions were monitored by 
Ppant ejection MS (83). The percent loaded ACP was determined by dividing the 
amount of loaded ACP by the total amount of ACP (holo plus loaded ACP). Both 
Figure 4.4  HPLC assay of AprA di-domain decarboxylation activity.  
 
The AprA di-domain was incubated with either malonyl-CoA (A) or 
methylmalonyl-CoA (B) for four hours at 30°C to assess decarboxylation 
activity. The CurA GNAT was used as a positive control for both malonyl-CoA 
(C) and methylmalonyl-CoA (D). The peak at ~11.5 min is CoA.  
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AprA ΔACP and AprA di-domain displayed acyltransfer activity with a clear 
substrate preference: acetyl-CoA > propionyl-CoA >> malonyl-CoA > 
methylmalonyl-CoA (Figures 4.5A and B). A competition experiment performed 
with an equimolar mixture of the four acyl-CoAs showed the same trend for both 
AprA variants (Figure 4.5D). Thus, acetyl-CoA is the preferred in vitro substrate 
of those tested, with only very slow transfer of the negatively charged acyl 
groups. The two AprA variants had similar rates of acyltransfer for each acyl-CoA 
(Figure 4.5C). These data show that the charged, bulky carboxylic acid 
containing malonyl and methylmalonyl-CoA are much poorer acyltransfer 
substrates then are either the uncharged acetyl- or propionyl-CoA. Combined 
with the apparent lack of decarboxylation activity this indicates that neither 
malonyl- nor methylmalonyl-CoA are likely to be the in vivo substrate of AprA. 
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4.4.4 Crystallization and overall structure of the AprA Di-domain 
The AprA di-domain used for activity assays (amino acids 503-1050) was highly 
stable, but did not crystallize. The recent crystal structure of CurJ CMT (54), 
which is homologous to AprA MT2, suggested the possibility that the MT2 C-
terminus was earlier in the sequence than previously thought. A new AprA di-
domain (503-1022) was also highly soluble and crystallized readily. An initial 
crystal form grew as large hexagonal rods in a few hours at both 4°C and 20°C, 
but diffracted to only ~6Å and was recalcitrant to optimization. More extensive 
Figure 4.5  AprA acyltransfer activity.  
 
AprA di-domain (A) or AprA ΔACP (B) was incubated with either acetyl-, 
propionyl-, malonyl, or methylmalonyl-CoA at 30°C with time points taken at 0, 
30, 60, 90, 120, and 180 min. The % Loaded ACP indicates the conversion of 
holo-ACP to the appropriate acyl-ACP, as evaluated by LC/MS with Ppant 
ejection. C) AprA di-domain and AprA ΔACP had nearly identical activity with 
all substrates tested. D) Competition assays with both AprA di-domain and 
AprA ΔACP with an equimolar mixture of acyl-CoAs.  The substrate selectivity 
was identical to the individual assays with a strong preference for acetyl-CoA. 
 99  
screening produced a second crystal form of thin plates that grew in a few days 
(Figure 4.6B). The addition of SAM to the crystal drop generally improved both 
the size and morphology of the crystals. The second crystal form diffracted to 
~2.5Å and was used to determine the di-domain structure (Table 4.1). The di-
domain consists of two distinct, noninteracting domains connected by a short 
tether (Figure 4.6A). Overlay with the CurA GNAT reveals that the AprA GNAT is 
highly truncated (Figure 4.6C). In contrast, the AprA MT2 and the CurJ CMT are 
highly similar throughout the domain (Figure 4.6D). 
 
4.4.5 Comparison of the AprA GNAT and CurA GNAT domains 
Approximately half of the CurA GNAT domain is not present in the AprA GNAT 
(Figure 4.6C). Moreover, the positions of active site tunnels for the ACP and CoA 
Ppant groups in the CurA GNAT are blocked by loops in the AprA GNAT (Figure 
4.7A). A topology diagram of the AprA and CurA GNAT domains shows that 
almost half of the central β-sheet, which is conserved in all GNAT superfamily 
members, is not present in the AprA GNAT (Figure 4.7B). A structure-based 
sequence alignment also clearly indicates that both decarboxylation-essential 
amino acids (His and Thr) in the CurA GNAT are absent in the AprA GNAT 
(Figure B.3). This leads to the conclusion that the AprA GNAT domain does not 
contain the catalytic machinery to perform either the decarboxylation or 
acyltransfer reactions. Therefore, my working hypothesis is that the GNAT 
domain is vestigial. Because the acyltransfer assay showed that the di-domain 
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catalyzes the acyltransfer reaction, I further hypothesize that the MT2 domain 
performs the acyltransfer reaction.  
 
Figure 4.6 The structure of the AprA GNAT-MT2 di-domain.  
 
A) Overall structure of the AprA di-domain, with magenta GNAT, light blue 
MT2 seatbelt helix, dark blue lid domain, sky blue core domain, and bound 
SAH in orange ball-and-stick. B) AprA di-domain crystal. C) Structural 
alignment of AprA GNAT domain (magenta) and the CurA GNAT domain 
(yellow). The overall RMSD is 2.7 Å for 66 Cα atoms. D) Structural alignment 
of the core domains of the AprA MT2 domain (blues) and the CurJ CMT 
domain (green) with SAH in orange ball-and-stick. The overall RMSD is 1.1 Å 
for 225 Cα atoms. 
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4.4.6 The AprA MT2 domain structure 
Although the AprA GNAT domain is highly divergent from its closest homologues, 
the AprA MT2 domain is highly similar to the CurJ CMT (54) (Figure 7D). The 
similarity includes an N-terminal “seatbelt” helix, which in the CurJ CMT brings 
the N- and C-termini close together and is proposed to be important for proper 
domain arrangement in PKS extension modules (54).  However, this N-terminal 
region of the CurJ MT has low sequence identity with the AprA MT2 (Figure B.4). 
This was a major source of uncertainty in the original analysis of AprA domain 
boundaries. All designs of single-domain AprA fragments assumed that GNAT 
had a similar length to the CurA GNAT when in fact the AprA GNAT is 75 amino 
acids shorter.  
 
Strong electron density in the MT2 active site was easily fit as the S-
adenosylhomocysteine (SAH) demethylation product of SAM, which was 
included in the crystallization solution (Figure 4.8A). The homocysteine portion of 
SAH was poorly ordered in the crystal structure. The homocysteine portion of 
SAH is known to interact with the GxGxG motif and was positioned accordingly. 
Superposition of the AprA MT2 and CurJ CMT structures shows good agreement 
of the SAH positions (Figure 4.8B). 
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Figure 4.7  Comparison of the AprA and CurA GNAT domains.  
 
A) Structural alignment of the AprA GNAT domain (magenta) and the CurA 
GNAT domain (yellow) with important CurA residues shown in ball and stick, 
the CurA bound acetyl-CoA and modeled ACP Ppant in black ball-and-stick, 
the CurA acetyl-CoA binding tunnel in wheat and the CurA Ppant binding 
tunnel in orange. B) Topology diagrams of the CurA GNAT and the AprA 
GNAT domains. Portions of the AprA GNAT that align to the CurA GNAT are 
shown in identical colors. The portion of the central β-sheet that is conserved 
between the structures is shown in a light blue box. Unique portions of the 
AprA GNAT structure are shown in magenta.  
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AprA MT2 has a long tunnel running along a cleft between the core and lid 
domains covered by a connecting “junction” helix (Figure 4.9A). The junction 
helix of the CurJ CMT is flexible and is proposed to interact with bound 
substrates (54). The junction helix of AprA MT2 also appears to be flexible and 
adopts a slightly different conformation than the CurJ CMT junction helix (Figure 
4.9B). Two Phe side chains of the MT2 junction helix that face the active site, 
Phe793 and Phe797, are both poorly ordered (Figure 4.9C), supporting the 
earlier proposal. Further evidence of substrate induced conformation changes 
can be seen with the core and lid domains. With the core domains of CurJ CMT 
and AprA MT2 aligned (RMSD 0.6Å) it can also be seen that the lid domains are 
in slightly different positions relative to the core domains (Figure 4.6D). The lid 
domains themselves are also highly similar (RMSD 1.7Å). This reinforces the 
previous observation that the core and lid domains move relative to each other 
and that this movement likely changes the substrate tunnel in response to 
substrate binding (54). The His and Glu catalytic dyad amino acids shown to be 
critical for methylation by the CurJ CMT are present in identical positions in AprA 
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4.4.7 Methyltrasferase Activity of AprA 
Prior to determining the crystal structure of the AprA di-domain, substantial effort 
was put into demonstrating the ability of the AprA MT domains to perform SAM-
dependent methylation. Based on prior hypotheses of AprA function, efforts were 
focused on acetyl- and propionyl-ACP as substrates. No methylation was 
detected with either substrate. Methylation of malonyl or methylmalonyl groups 
was also not detected, consistent with previous reports on natural product MT 
domains (54,118,119).  
 
Figure 4.8  The AprA MT2 SAM binding site. 
 
A) Fo-Fc omit map at 3σ generated with simulated annealing shown as green 
mesh. The homocysteine portion of SAH is poorly ordered. Protein shown in 
sky blue ball-and-stick or cartoon. SAH shown in orange ball-and-stick. His914 
and Glu940 constitute the catalytic dyad. Gly839 and Gly841 make up part of 
the GxGxG SAM binding motif, Gly837 is obscured by the SAH ribose. B) 
Structural alignment of the core domains of the AprA MT2 domain (sky blue) 
and the CurJ CMT domain (green). SAH is shown as ball-and-stick in orange 
(AprA MT2) and green (CurJ CMT).  
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Figure 4.9  The AprA MT2 substrate binding tunnel and conserved active site.  
  
A) The active site sits at the interface between the core and lid domains. The 
seatbelt helix of MT2 is shown in light blue, the lid domain in blue, the core 
domain in sky blue, the bound SAH in orange ball-and-stick, and the catalytic 
dyad in chartreuse ball-and-stick. The active site tunnel is shown as a warm pink 
surface created with Caver (120). B) The junction helix (yellow) adopts a new 
conformation in AprA MT2 compared to the CurJ CMT (green). C) The junction 
helix appears to be flexible, as demonstrated by two junction helix residues, 
Phe793 and Phe797, which face the active site and are poorly ordered. Phe797 
is best modeled as two conformations with each at 50% occupancy. 2Fo-Fc map 
contoured at 1σ shown in green-cyan mesh.  
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1Values in parentheses pertain to outermost shell of data. 
 
Data Collection  
Space group C2 
Cell dimensions a,b,c 
(Å) 
152.0, 54.6, 109.7  
α,β,γ (°)  90, 131.9, 90  
X-ray source APS 23ID-B 
Wavelength (Å) 1.033 
dmin (Å) 2.50 (2.59-2.50)
1 
Rmerge 0.129 (1.22)  
Wilson B factor 25.0 
Avg I/σ(I) 11.18 (1.45) 
Completeness (%) 98.0 (99.0) 
Multiplicity 6.8 (7.0) 
Total observations 159,576  
(16,137) 
CC1/2 0.997 (0.512) 
CC* 0.999 (0.823) 
Refinement  
Data range (Å) 49.21-2.50 







  protein 4,107 
  ligands 27 
  water 202 




  bond lengths (Å) 0.008 
  bond angles (°) 1.05 
Average B-factor 38.4 
  macromolecules 38.6 
  ligands 65.6 
  solvent 34.1 
Ramachandran plot  
  favored (%) 96.2 
  allowed (%) 3.6 
  outliers (%) 0.2 
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The high structural similarity of the MT2 domain to the CurJ CMT domain (54), 
especially in their active sites, prompted the testing of acetoacetyl-ACP as a 
potential methylation substrate. Surprisingly, when incubated overnight with 
acetoacetyl-ACP and SAM, the AprA di-domain (503-1022) completely converted 
acetoacetyl to dimethyl-acetoacetyl (Figure 4.10). Currently, it is not known if 
acetoacetyl is the in vivo substrate of AprA, but these data indicate that the 
methyltransfer reaction requires a more reactive carbon then the acetyl or 
propionyl groups previously hypothesized.  
 
4.5  Conclusion and Future Directions 
The data presented here show that the AprA loading module diverged from other 
GNAT-based loading modules. Initial experiments showed that AprA does not 
possess the acyl-CoA decarboxylation activity previously observed with the CurA 
GNAT. In addition, AprA was shown to prefer acetyl- and propionyl-CoA 
Figure 4.10  Methylation activity of AprA di-domain.  
 
LC-MS analysis of AprA di-domain methyltransfer activity showing intact 
protein MS (A) and Ppant ejection MS (B). For the assay, Sfp-loaded 
acetoacetyl-ACP was incubated at 30°C with AprA di-domain and SAM for 17 
hr. See Table B.2 for calculated and observed masses. NEC: No Enzyme 
Control.  
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substrates for the acyltransfer reaction in vitro. It was therefore hypothesized that 
either acetyl- and propionyl-ACP was the initial substrate for the 
methyltransferase domains. Extensive efforts to elicit methylation on either 
acetyl- or propionyl-ACP were unsuccessful.  
 
The recently solved structure of the CurJ CMT (54) provided valuable insights 
into the AprA MT2 domain that allowed for the determination of the AprA di-
domain structure and subsequent demonstration of acetoacetyl-ACP di-
methylation. These recent findings provide a tantalizing hint at the in vivo function 
of AprA, and indicate that previous thinking on the function of AprA requires 
significant re-evaluation. The following is a brief list of points that must be 
addressed to begin to understand AprA.  
 
The biggest outstanding question is, what are in vivo substrates of AprA? 
Previously it was thought that the GNAT domain transferred an acetyl or 
propionyl group from CoA to the AprA ACP followed by three or two, respectively, 
SAM-dependent methylations to generate the t-butyl group. The revelation that 
acetoacetyl-ACP is an MT2 methylation substrate indicates that a more activated 
carbon is required for methylation. This leads to a number of questions regarding 
a synthetic scheme for generating both an activated carbon and the final t-butyl 
group. Obviously much more study of both the acyltransfer and methylation 
reactions is required.   
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As had been noted previously, the sequence alignments for the N-terminal 
portions of MT2 domain and most of the GNAT domain were poor. This led to an 
unclear boundary between the two domains. The di-domain structure has 
allowed for the domain boundaries between the two domains to be assigned. 
Additionally, the lack of interaction between the domains indicates that they could 
be separable. Producing individual domains would allow for testing of the 
hypothesis that MT2 catalyzes the acyltransfer reaction in place of a catalytically 
dead, vestigial GNAT domain. 
 
The AprA MT1 domain is conserved in a number of other GNAT-based loading 
modules that apparently require methylation to generate their products (Figure 
4.2). Thus far, no biochemical characterization of these MT domains has been 
reported. Our demonstration of methylation of acetoacetyl-ACP by the AprA MT2 
again indicates that the previously proposed reaction schemes are likely to be 
incorrect. AprA MT1 likely plays a role in the generation of the t-butyl group, but 
with the current number of outstanding questions it is difficult to ascribe MT1 a 
function. Investigating MT1 function through the study of the MT domain of a 
homologous loading module may significantly reduce the complexity of 
experiments by eliminating MT2. These and many more questions about AprA 
function must be addressed to fully understand the function of this remarkable 
enzyme.  
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4.6  Methods and Materials 
4.6.1 Cloning and Sequence Alignments 
AprA residues 2-1138 were amplified from Moorea bouillonii fosmid 11H10 (4) by 
PCR and inserted into pMCSG7 by LIC (105) to create pMCSG7-AprA and 
verified by sequencing. Subsequent constructs were created by subcloning from 
pMCSG7-AprA using identical methods. See Table B.1 for full list of constructs 
and primers. Sequence alignments were created using Jalview (76,77) using the 
Clustal O (78). 
  
4.6.2 Bacterial strains, media and culture conditions 
Cultures were grown in Terrific Broth (TB) medium containing 4% glycerol. 
Ampicillin (100 μg/mL, pMCSG7), spectinomycin (50 μg/mL, pRARE), and 
chloramphenicol (35 μg/mL, pG-KJE8) were used with the corresponding 
plasmids in E. coli cultures. E. coli strain BAP1 (65) was transformed with 
pMCSG7-AprA_ACP. Strain BL21(DE3) containing the pRARE (106) and pG-
KJE8 (Takara Bio) plasmids was transformed with pMCSG7-AprA and pMCSG7-
AprA_ΔACP. Remaining plasmids were transformed into strain BL21(DE3) 
containing no additional plasmids. Cultures were grown at 37°C in 500 mL TB to 
an OD600 of 1.5, cooled to 20°C for at least 1 hr, induced with IPTG (final 
concentration 0.2 mM), and grown for an additional 14-18 hr before harvesting by 
centrifugation. Cell pellets were stored at -20°C until used for protein purification.  
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4.6.3 Purification of AprA Proteins  
Cell pellets were resuspended in approximately 5 mL Buffer A (50 mM HEPES 
pH 7.0, 50 mM AmSO4, 10% glycerol) containing 15 mM imidazole per 1 g cell 
paste. All purification steps were performed at 4°C. Resuspended cells were 
incubated with DNase (4 mg), lysozyme (10 mg), and MgCl2 (4 mM) for 30 min, 
then lysed by three passes though an Avestin EmulsiFlex-C3 homogenizer and 
clarified by centrifugation at 30,000 xg. The soluble fraction was loaded onto a 5-
mL HisTrap Ni NTA column (GE Healthcare) in Buffer A and eluted with an 
imidazole gradient from 30-300 mM. The eluted protein was further purified via 
size exclusion chromatography with a HiLoad 16/600 Superdex 200 column (GE 
Healthcare) in Buffer A. Final fractions were pooled, concentrated, flash cooled 
with liquid N2, and stored at -80°C. AprA ACP was purified identically to AprA 
enzymes except the initial buffer was 100 mM Tris pH 7.5, 500 mM NaCl, 10% 
glycerol, 5 mM TCEP and the size exclusion chromatography buffer was 100 mM 
Tris pH 7.5, 250 mM NaCl, 5% glycerol, 5 mM TCEP. 
 
4.6.4 Purification of AprA di-domain for Crystallization 
AprA di-domain (503-1022) for crystallization was purified identically to other 
AprA proteins except Buffer C (100 mM Tris pH 7.9, 500 mM NaCl, 5% glycerol) 
was used in the initial HisTrap Ni NTA column, and steps of TEV protease 
cleavage and second HisTrap Ni NTA column were added to the protocol. The 
eluted protein from the first HisTrap Ni NTA was cleaved with TEV protease (1:30 
ratio TEV:AprA di-domain with 2 mM DTT) and dialyzed into Buffer D (50 mM 
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Tris pH 7.9, 100 mM NaCl, 10% glycerol). The digested protein was run over a 
second 5-mL HisTrap Ni NTA column. The cleaved AprA protein in the flow-
through fraction was purified via size exclusion chromatography with a HiLoad 
16/600 Superdex 200 column (GE Healthcare) in Buffer E (50 mM Tris pH 7.9, 
100 mM NaCl). Final fractions were pooled, concentrated, flash cooled with liquid 
N2, and stored at -80°C. 
 
4.6.5 Purification of CurA GNAT 
Plasmid pMCSG7-GNATL (35) was used to express CurA GNAT, which was 
purified identically to the AprA di-domain protein except the buffer for the HisTrap 
Ni NTA column was 100 mM Tris pH 7.9, 300 mM NaCl, 10% glycerol, TEV 
protease cleavage was done in Buffer F (20 mM Tris pH 7.9, 300 mM NaCl, 10% 
glycerol). The tag-free protein was further purified via size exclusion 
chromatography with a HiLoad 16/600 Superdex 200 column (GE Healthcare) in 
Buffer F. Final fractions were pooled, concentrated, flash cooled with liquid N2, 
and stored at -80°C. 
 
4.6.6 Crystallization 
AprA di-domain (503-1022) was crystallized from a 5 mg/mL stock solution in 
Buffer E with 1 mM SAM using micro seeding from seed stocks generated using 
Seed Beads (Hampton). Crystals grew in 2-4 days at 20°C by vapor diffusion in 
1.7 μL sitting drops containing 0.75 μL protein stock, 0.2 μL seed stock, and 0.75 
μL reservoir solution (0.01-0.05M trimethylamine N-oxide, 12-17% PEG 8000, 
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0.12M Tris pH 7.5). Crystals were harvested in nylon loops, cryoprotected with 
reservoir solution containing 10% glycerol, and flash cooled in liquid N2. 
 
4.6.7 Diffraction Data Collection and Structure Determination 
Diffraction data were collected at 100 K on GM/CA beamline 23ID-B at the 
Advanced Photon Source (APS) at Argonne National Laboratory (Argonne, IL). 
For each crystal, 360º of data were collected using 0.2º rotation and 0.2 sec 
exposure per image (Table 4.1). Data were processed using XDS (68). The 
structure of AprA di-domain with bound SAH was solved by molecular 
replacement (MR) with Phaser (69) in the PHENIX software suite (70) using 
search models created with sculptor (121) from the CurJ CMT (33% identity, 
PDB code: 5THY) (54) and CurA GNAT (24% identity, PDB code: 2REE) (35) as 
search models. The initial model from MR was modified with AutoBuild (71) to 
generate a 77% complete model of AprA di-domain. The remaining portion of 
model was completed manually using Coot (72). Refinement was performed 
using phenix.refine (73). Images and figures were prepared using PyMOL (82) 
and CAVER (120). Topology diagrams were generated using Pro-origami (122). 
The structure was validated with MolProbity (81). 
 
4.6.8 CoA Decarboxylation Assay 
The decarboxylation activity of AprA proteins was investigated using a modified 
version of the decarboxylation assay previously used to characterize the CurA 
GNAT (35). Briefly, 10 μM of enzyme (di-domain (503-1050)) was combined with 
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500 μM of either malonyl of methylmalonyl-CoA in reaction buffer (10 mM MgCl2, 
5 mM TCEP, 100 mM Tris pH 7.5). Reactions were run at 30°C for 4 hours and 
then quenched with 10% formic acid. HPLC analysis was performed on an 
Agilent 1290 HPLC system by RP-HPLC (Luna C18(2) 5μ C18 column 100Å, 250 
X 4.6 mm) with a 30 min gradient of 3-90% methanol with 10mM ammonium 
acetate at a flow rate of 1.0 mL/min. CurA GNAT was used as a positive control.  
 
4.6.9 Acyl Transfer Activity Assay 
The acyl transfer activity of AprA proteins was investigated using a mass 
spectrometry based phosphopantetheine (Ppant) ejection assay (83). 25 μL 
reaction mixtures consisted of 100 mM Tris pH 7.5, 10 mM MgCl2, 5 mM TCEP, 
500 μM acyl-CoA, 10 μM AprA enzyme (di-domain (503-1050) or ΔACP), and 50 
μM AprA holo-ACP. Reactions were incubated at 30°C until quenched with 10% 
formic acid, time points were taken at 0, 30, 60, 90, 120, and 180 min. The 
competition assay was run using a 1:1:1:1 mix of acetyl-, propionyl-, malonyl-, 
and methylmalonyl-CoA (500 μM each) for 180 min. A reaction mixture without 
an AprA enzyme was used as a negative control. Reaction mixtures were 
prepared for mass spectrometry (MS) by binding to a spin column packed with 40 
μ C4 resin (Analtech B265A BME) equilibrated with water containing 0.1% formic 
acid. Samples were washed twice with 120 μL water containing 0.1% formic acid, 
and eluted with 30 μL acetonitrile with 0.1% formic acid. Samples were spun at 
4,000 xg for 2 min after each step. 10 μL of prepared sample was injected onto 
an Agilent 6520 Q-TOF mass spectrometer equipped with an Agilent 1290 HPLC 
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system. Samples were separated for MS analysis by RP-HPLC (Aeris widepore 
C4 column 3.6 μM, 50 X 2.10 mm) with a 10 min gradient of 10-95% acetonitrile 
with 0.1% formic acid at a flow rate of 0.5 mL/min and Ppant ejection data was 
(83). Ppant ejection data were analyzed using the Agilent Mass Hunter 
Qualitative Analysis software with the maximum entropy deconvolution algorithm. 
The percent loaded ACP with each of the four acyl groups was calculated for 
each time point using the area of the ejected Ppant peaks and the following 
equation: 
                 
       
                                                           
 
 
4.6.10 Methyltransferase Activity Assay 
Methyltransferase activity was assessed using an MS-based Ppant ejection 
assay similar to that used to assess acyl transfer activity. 50 μL reaction mixtures 
consisted of 50 mM HEPES pH 7.4, 1 mM MgCl2, 500 μM acetoacetyl-CoA, 25 
μM AprA Di-domain (503-1022), 10 μM Sfp (66), and 100 μM apo AprA ACP. 
Reactions were incubated at 30°C for 17 hrs and then quenched with 1% formic 
acid. A reaction mixture without enzyme was used as a negative control. 0.5 μL 
of reaction mixture was injected onto an Agilent 6545 Q-TOF mass spectrometer 
equipped with an Agilent 1290 HPLC system and separated for MS analysis by 
RP-HPLC (Aeris widepore C4 column 3.6 μM, 50 X 2.10 mm) with a 10 min 
gradient of 10-95% acetonitrile with 0.1% formic acid at a flow rate of 0.5 mL/min. 
Intact protein and phosphopantetheine ejection data were analyzed using the 
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Agilent Mass Hunter Qualitative Analysis software with the maximum entropy 
deconvolution algorithm. 
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Appendix B 
 





Figure B.1  Sequence alignment of loading module AR domains.  
 
Amino acid numbers in the figure correspond to the AR domain within each 
multidomain protein. Protein abbreviations (GenBank accession codes) are as 
follows: CurA - curacin A (AEE88289.1), SxtA - saxitoxin (ABI75094.1), TaI - 
myxovirecin (WP_011553948.1), GphF - gephyronic acid (AHA38199.1), RhiA 
- rhizoxin (WP_013435483.1). 
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Figure B.2  Sequence alignment of AprA MT1 and loading module MT 
domains.  
 
The SAM binding consensus sequence is indicated. Amino acid numbers in 
the figure correspond to the MT domain within each multidomain protein. 
Protein abbreviations (GenBank accession codes) are as follows: SxtA - 
saxitoxin (ABI75094.1), TaI - myxovirecin (WP_011553948.1), GphF - 
gephyronic acid (AHA38199.1). 




Figure B.3  Sequence alignment of loading module GNAT domains with AprA 
and CurA secondary structure notations.  
 
The conserved decarboxylation residues identified  in the CurA GNAT are 
marked with asterisks. Amino acid numbers in the figure correspond to the 
GNAT domain within each multidomain protein. Protein abbreviations 
(GenBank accession codes) are as follows: CurA - curacin A (AEE88289.1), 
SxtA - saxitoxin (ABI75094.1), TaI - myxovirecin (WP_011553948.1), GphF - 
gephyronic acid (AHA38199.1), RhiA - rhizoxin (WP_013435483.1), NspA - 
nosperin (ADA69237.1), Bat1 - batumin (WP_052451043.1), OnnB - 
onnamide (AAV97870.1), PedI - pederin (AAR19304.1), BonA - bongkrekic 
acid (AFN27480.1). 
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Figure B.4  Sequence alignment of the AprA MT2 domain and PKS C-MT 
domains with AprA secondary structure notation.  
 
MT motifs are labeled. Amino acid numbers in the figure correspond to the MT 
domain within each multidomain protein. Pathway abbreviations (GenBank 
accession codes) are as follows: Cur - curacin A (HQ696500.1), Jam - 
jamacamide (AY522504.1), Crp - cryptophycin (EF159954.1), Hct - 
hectochlorin (AY974560.1), Mcy - microcystin (KC699835.1), Gph - 
gephyronic acid (KF479198.1), HMWP1- yersiniabactin (AE009952.1), Epo - 
epothilone (AF217189.1), Rhi - rhizoxin (AM411073.1), Sor - sorangicin 
(HM584908.1), Cal - calyculin (AB933566.1), Bon - bongkrekic acid 
(AFN27480.1), Lov - lovastatin (AF151722.1, AH007774.2), SQTKS - 
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apo ACP 12235.0  None N/A N/A 
holo ACP 12575.1 12575.2 261.13 216.13 
acetoacetyl ACP 12659.1 12659.2 345.15 345.15 
methyl-acetoacetyl ACP 12673.1 None 359.16 None 
dimethyl-acetoacetyl 
ACP 
12687.1 12687.4 373.18 373.18 
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Chapter V 
 
Conclusions and Future Directions 
 
Conclusions 
5.1  Overview 
Initiation is a critical step in natural product biosynthesis. The studies presented 
here broadened our understanding of the initiation steps though structural and 
biochemical investigations of three biosynthetic pathways: the olefin synthase of 
the marine cyanobacterium Synechococcus sp. PCC 7002, the cahuitamycin 
pathway of Streptomyces gandocaensis, and the apratoxin pathway of the 
marine cyanobacterium Moorea bouillonii. Observations are presented 
supporting a proposed mechanism of fatty acid chain-length selectivity used by 
the olefin synthase FAAL enzyme from Synechococcus sp. PCC 7002. 
Additionally, a rational structure-based explanation of substrate selectivity by the 
naturally promiscuous AMP-ligase CahJ from the cahuitamycin pathway was 
developed. Lastly, the structure of the GNAT-MT2 di-domain as well as the first 
activity data from the poorly understood AprA loading module from the apratoxin 
pathway is presented. These investigations have potential to form the basis of 
useful applications of the biosynthetic pathways. 
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5.2  An electrostatic fatty acid length selection mechanism by SynFAAL 
The first enzyme of olefin synthase pathways is an FAAL domain, which 
activates a fatty acids using ATP and transfers them to an ACP. In vivo studies 
indicated high selectively for stearic acid, since only 1-nonadecene was observed 
(3,30). The structure of the FAAL domain from the Synechococcus PCC 7002 
olefin synthase pointed to an electrostatic mechanism that selects against C16 
fatty acids and a substrate tunnel that is unable to accommodate fatty acids 
longer than 18 carbons. Combined with data showing that fatty acids shorter than 
16 carbons are rare in Synechococcus PCC 7002 (29), the preference for C18 
substrates provides an explanation for the high in vivo selectivity of the enzyme. 
This was further supported with mutagenesis experiments to decrease the 
electrostatic charge of the substrate tunnel, which resulted in improved 
hexadecanoic acid utilization. In addition, mutagenesis to introduce larger amino 
acid side chains to occlude the fatty acid binding tunnel demonstrated that the 
substrate selectivity of the enzyme could be tailored to accommodate different 
substrates.  
 
5.3  Understanding the substrate selectivity of the CahJ 
The naturally promiscuous AMP-ligase CahJ natively utilizes SA and 6-MSA as 
substrates. The biochemical and structural investigations of CahJ presented here 
provided both the scope of substrate utilization and a rational explanation of 
substrate utilization. In brief, the CahJ substrate binding site consists of a flat, 
hydrophobic site surrounded by binding pockets that correspond to substituent 
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positions of the central aromatic ring. The 2 position contains an Asn that forms a 
hydrogen bond with the 2-hydroxy group of salicylic acid. The 3 position is 
sterically restricted by Leu and Cys side chains and does not accommodate 
substituents well (Figure 3.5). The binding pockets at the 4, 5, and 6 positions 
are all large enough to accommodate methyl substituents; however, slight 
rotations of the aromatic ring are required for each substituent to fit into its 
binding pocket, making it difficult for multiple substituents to be present 
simultaneously. This understanding guided the creation of a new cahuitamycin 
congener, cahuitamycin F, which has anti-biofilm activity similar to cahuitamycin 
A. 
  
5.4  Investigations into AprA, the loading module of the apratoxin A 
biosynthetic pathway 
AprA, the loading module of the apratoxin biosynthetic pathway is a GNAT-based 
loading module, homologs of which are found at the beginning of approximately a 
dozen pathways. The structural data presented here shows that the GNAT 
domain is truncated and likely not catalytically competent. An AprA di-domain 
consisting of the GNAT and MT2 domains retains acyltransfer activity indicating 
that the MT2 domain may perform an acyltransfer reaction. If so, this would 
constitute the discovery of new chemistry for an enzyme with a type I 
methyltransferase fold. Also presented here is data showing the AprA GNAT-
MT2 di-domain performs the SAM dependent methylation of acetoacetyl-ACP to 
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form dimethyl-acetoacetyl-ACP, the first demonstration of methylation activity for 
a GNAT-based loading module. 
 
Future Directions 
5.5  Olefin production by the intact olefin synthase 
The biological production of length-specific olefins has potential applications in a 
number of contexts, including chemical feedstocks, lubricants, surfactants, and 
biofuels. The successful biological production of olefins for commercial use will 
require an understanding of the olefin synthase pathways that produces them. 
Olefin synthases are composed of three sections; the initiation FAAL domain, a 
canonical PKS extension module, and the terminal ST and TE domains. Previous 
studies of olefin synthases have elucidated the function of the ST and TE 
domains (32-34). The canonical PKS extension module has not been studied 
directly, but can be assumed to function in manner consistent with other PKS 
extension modules. With the additional findings presented here, all of the 
individual pieces of olefin syntheses are now reasonably well understood. The 
next step toward biological olefin production is investigating the full-length olefin 
synthase. Studies with the full-length olefin synthase are critical to determine if 
results showing the ability to control to length of the fatty acid selected by the 
FAAL domain can be propagated through the remainder of the olefin synthase, 
leading to the production of shorter olefin chains. This work would likely 
encounter technical hurdles; first, full-length olefin synthase is a very large 
protein (~300 kDa) that has not been previously purified and could be difficult to 
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produce in significant quantities. Second, the detection of free olefins at low 
concentrations to monitor the reaction could be challenging. This issue may be 
circumvented by monitoring the turnover of a co-factor such as NADPH by the 
KR domain, but the ideal method would detect olefin production directly. An 
assay of olefin production would allow the olefin synthase to be engineered to 
optimize olefin production for both chain-length specificity and yield. For the 
production of olefins to be practical for large-scale use they must produced in 
vivo. The best candidate would be likely a cyanobacterium because olefin 
synthases are natively found in cyanobacteria and should therefore be well 
expressed in cyanobacteria, and cyanobacteria are capable of carbon fixation 
and would require minimal nutrient input. 
 
5.6  Investigating short-chain FAAL enzymes 
Another route of investigation that furthers the goal of length-specific olefin 
production would be to characterize a short-chain FAAL enzyme. The data 
presented here showed that SynFAAL had low activity with fatty acid substrates 
shorter than 10 carbons. Instead of engineering SynFAAL to utilize short-chain 
fatty acids, it may be more effective to swap the SynFAAL for an FAAL that 
natively uses shorter fatty acids. A potential candidate would be JamA, which 
activates hexanoic acid (58,59). A methodical investigation of JamA substrate 
selectivity could be combined with investigations of the full-length olefin synthase 
by the replacement of SynFAAL with JamA to access olefin chain lengths not 
possible with the SynFAAL. If successful, the replacement of SynFAAL with other 
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FAAL enzymes, such as the medium-chain length enzyme ColA, may increase 
olefin production. 
 
5.7  Engineering the CahJ Substrate Binding Site 
A key factor in the success of the cahuitamycins as biofilm inhibitors may be the 
ability to easily produce new congeners. The work presented showed the native 
substrate range of CahJ and indicated that many more cahuitamycin congeners 
could be produced. However, as the biological mechanism of cahuitamycin 
activity is revealed, starter molecules incompatible with wild type CahJ may be 
needed for the creation of desired cahuitamycin congeners. Therefore, protein 
engineering to expand and/or alter CahJ substrate selectivity could have 
important future applications. Understanding the substrate binding requirements 
of CahJ has provided a roadmap for engineering to expand its substrate range. 
The 3 position pocket should be amenable to protein engineering given the 
natural variability at that position (Figure A.5B). Val330 at the bottom of the active 
site separates the 4 and 5 pockets and a glycine replacement would open a large 
binding volume (Figure A.5C). It may also be possible to restrict currently open 
binding pockets to create variants of CahJ with high selectivity for a desired 
substrate, thereby increasing production of a desired cahuitamycin congener 
while reducing the production of unwanted cahuitamycin congeners.  
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5.8  Continued biochemical investigations of AprA 
The insights provided by CurJ CMT rapidly lead to the structure of the AprA 
GNAT-MT2 di-domain by indicating that the di-domain C-terminus should be 
shortened by nearly 30 residues. The structure then provided valuable insights 
into AprA function. However, the story is far from complete. Foremost among the 
open questions is the identity of the native substrate for the acyltransfer reaction. 
Without the initial substrate as a starting point it will be difficult to propose an 
accurate reaction scheme that generates the final t-butyl-containing pivalyl-ACP. 
For example, the current biochemical data indicate that acetoacetyl-ACP is good 
substrate for dimethylation by MT2. Unfortunately, there is no clear route for the 
conversion of dimethyl-acetoacetyl-ACP to pivalyl-ACP. This leaves two 
possibilities, that acetoacetyl-ACP is not the native substrate, or that there is a 
cryptic conversion of dimethyl-acetoacetyl- to pivalyl-ACP. Both possibilities 
present interesting opportunities for the discovery of novel biochemical reactions. 
Knowing which acyl group is initially loaded should provide a base upon which 
the pivalyl-ACP can be built, and lead to testable hypotheses that guide the 
course of future investigations. Feeding studies of the apratoxin A producer, 
Moorea bouillonii, would also provide additional data by placing constraints on 
the number of possible mechanisms that must be considered. The MT1 domain 
of AprA has not yet been assayed successfully, but this domain likely plays some 
role in the generation of pivalyl-ACP and also warrants continued biochemical 
study. 
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